{"prompt": "System: \nMake reference to the context given to assess the scenario. If you do not know the answer. just say that \"I don't know\", don't try to make up an answer.\nYou are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC).\n\nANALYSE the given patient profile based on given query based on one of the following criteria:\n- Whether treated patient is new patient or patient under maintenance\n- Prior response to Infliximab\n- Prior failure to Anti-TNF agents\n- Prior failure to Vedolizumab\n- Age\n- Pregnancy\n- Extraintestinale manifestations\n- Pouchitis\n\nFINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.\nOutput your answer as a list of JSON objects with keys: drug_name, advantages, disadvantages.\n\nsummaries\n\nHuman: question", "test_cases": [{"question": "40 year old male with newly diagnosed moderate UC and articular extraintestinal manifestations\n", "answer": "[{\n\"drug_name\": \"Infliximab\",\n\"advantages\": \"Infliximab has been shown to be effective in treating both UC and rheumatological manifestations, making it a good choice for patients with articular extraintestinal manifestations. It is also well-established and supported by multiple trials.\",\n\"disadvantages\": \"Infliximab is an intravenous drug, which may not be convenient for all patients. It can also cause side effects such as infections, allergic reactions, and liver damage. Additionally, some patients may develop antibodies to infliximab, reducing its effectiveness.\"\n},\n{\n\"drug_name\": \"Ustekinumab\",\n\"advantages\": \"Ustekinumab is another option for patients with substantial comorbidities or contraindications to TNF antagonists. It is also effective in treating both UC and extraintestinal manifestations.\",\n\"disadvantages\": \"Ustekinumab may not be as effective as Infliximab in treating articular manifestations. It also requires subcutaneous injections, which some patients may find inconvenient or uncomfortable. Side effects can include infections, allergic reactions, and potential risk of cancer.\"\n}]", "sources": [{"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2.0, "text": "Numerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated\nwith an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD\ncompared to the general pediatric population.46 Similar to\nthe youngest patients with IBD, elderly-onset IBD (diag-\nnosed at 60\u201365 years of age) has con\ufb02icting evidence on\nprognosis, with 1 study reporting fewer hospitalizations and\nless frequent requirement of immunosuppression in pa-"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 4.0, "text": "in\ufb02iximab therapy (Nguyen et al., 2015).\nExtraintestinal manifestations occur in half of IBD patients and\nrepresent an important cause of morbidity and disability (Vavricka et al.,\n2011; Juillerat et al., 2020). Among EIMs, articular manifestations affect\n30% of patients. They include non-in\ufb02ammatory joint pain as well as\nin\ufb02ammatory joint manifestations including axial arthritis considered as\nspondyloarthropathies. Since their approval in IBD, in\ufb02iximab and later\nthe other anti-TNF agents represent the best treatment choice in IBD\npatient with rheumatological manifestations, supported by multiple trials\nin both CD and UC, in addition to their well-established ef\ufb01cacies in most\nrheumatological indications (Herfarth et al., 2002; Generini et al., 2004;\nLofberg et al., 2012; Louis et al., 2018).\nVedolizumab may not represent the most appropriate biologic in\npresence of articular manifestations of IBD. Indeed, by virtue of its"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2.0, "text": "Therefore, a consideration of risks, bene\ufb01ts, and alternatives\nis key to develop an individualized therapeutic plan for the\ninformed patient.\nIt is important to differentiate between disease activity\nand severity. Although the former refers to the burden of\nin\ufb02ammation at any given point in time, the latter takes into\naccount the disease phenotype and course, and is helpful in\ndetermining\nprognosis\nand\npredicting\ncomplications\n(Figure 1). For example, a patient with low disease activity\n(little to no symptoms and low in\ufb02ammatory markers) may\nactually have high severity (due to disease history or\nbehavior) increasing the risk for disease progression, and\nshould be managed more proactively and aggressively. We\nwill review predictors of IBD severity and activity.\nAge of In\ufb02ammatory Bowel Disease Diagnosis\nNumerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 1.0, "text": "de\ufb01ciencies, altered eating habits, in\ufb02ammatory cytokines,\nand corticosteroid use. Marked growth impairment at\ndiagnosis, de\ufb01ned as a height z-score < \u20132.5, is a poor\nprognostic sign.31 Furthermore, IBD patients exhibit \u201ccatch\nup\u201d growth beyond the typically expected age for growth\nplate closure (median additional years to reach adult height:\nmale patients with CD, 1.9 years and male patients with UC,\n2.5 years; female patients with CD: 2.6 years and female\npatients with UC, 2.8 years), suggesting that achieving\nremission even after reaching adolescence may allow for\nmaximal growth potential.18\nEarly Management Can Alter Disease Course and\nPrevent Complications\nData have consistently demonstrated that long-term IBD\ncomplications are mitigated by early treatment and remis-\nsion. In the long-term follow-up data from the CALM trial,\npatients with early CD who achieved deep remission,\ncompared to those who did not, had a signi\ufb01cantly lower"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 8.0, "text": "therapy in UC and it can be stopped in patients escalating to\nbiologics.110 Some patients may present with acute severe\nUC\nwhere\nTNFi,\ncyclosporine,\nor\nsubtotal\ncolectomy\nfollowed by ileal pouch anal anastomosis can be a good\ninitial strategy; discussion of management of acute severe\nUC is beyond the scope of this article.\nTaking Extraintestinal Manifestation Into\nConsideration\nEIMs are common in IBD, estimated to affect 30%\u201340% of\npatients.111,112 In a Swiss cohort study, symptoms of EIMs\nbefore IBD in one-quarter of the patients113; collaboration\nacross specialties, including but not limited to rheumatolo-\ngists, dermatologists, ophthalmologists, is vital not only to\nprompt referral of patients with EIM suspicious for IBD to\nallow for expedient initiation of therapy for both conditions,\nbut also to allow for consideration of both in the selection of\ntherapy, dose, and chronicity of treatment. For example, VDZ,\nwhich is gut-selective, is associated with an increased risk of"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "grated synthesis of risk benefits from diverse evidence sources, includ-\ning head-to-head trials, real-world evidence, and patients\u2019 values and \npreferences, can inform the optimal positioning of therapies to improve \npatient outcomes. In the future, prognostic and predictive biomarkers \nin conjunction with clinical factors might help make precise decisions.\nSiddharth Singh\u2009\n \u2009 \nDivision of Gastroenterology, University of California San Diego,  \nLa Jolla, CA, USA.  \n\u2009e-mail: sis040@ucsd.edu\nPublished online: 27 January 2023\nRisk of disease-related\ncomplications (disease severity)\nRisk of treatment-related\ncomplications (comorbidities)\nFirst-line therapy\n\u2022 Vedolizumab monotherapy (moderate\n disease); ozanimod as an oral alternative\n\u2022 Infliximab, preferably in combination with  \n immunomodulators (severe disease,  \n \n extraintestinal manifestations)\n\u2022 Ustekinumab (for patients with substantial \n comorbidities or  contraindications to TNF  \n antagonists)\nFirst-line therapy"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 1.0, "text": "10 years after diagnosis, respectively, and has decreased\nsigni\ufb01cantly during the last 6 decades.14\nThe symptoms associated with IBD can be waxing and\nwaning, but the underlying systemic in\ufb02ammation can lead\nto progressive, cumulative, and often irreversible intestinal\ndamage\nand\nrisk\nof\ncomplications\nif\nnot\ntreated\nadequately.15\nComplications\nassociated\nwith\nongoing\nin\ufb02ammation in CD include strictures, obstructions, \ufb01stulas,\nabscesses, and surgery,3,16 and those associated with UC\ninclude loss of colonic and anorectal function, surgery, and\ncolorectal cancer.2,4,17 Other complications include anemia,\nnutritional de\ufb01ciencies, loss of bone density, and progres-\nsive loss of quality of life. In children, persistent in\ufb02amma-\ntion\nis\nassociated\nwith\ngrowth\nimpairment,\nrisking\npermanent loss of height.18 Similar to other chronic dis-\neases, such as rheumatoid arthritis, the concept of cumula-\ntive damage is now acknowledged in IBD and can be"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 1.0, "text": "perianal CD varied between 11% and 19% at 1\u201310 years\nafter diagnosis.9 In a study of 983 patients with CD in Asia,\nstricturing or penetrating CD occurred in 41% and perianal\ndisease in 25% of patients.10 At the other end of the spec-\ntrum, incidental terminal ileitis can be diagnosed in 1.6% of\nindividuals undergoing nondiagnostic colonoscopy, with an\nuncertain but likely low rate of progression to overt CD.11\nWith respect to UC, most patients have mild to moderate\nseverity and 10%\u201315% of patients can experience a severe\ncourse.12 In a population-based cohort study, proctosigmoid\nlocation of colitis occurred in 73% of patients; of these,\ndisease extension occurred in 23% of patients at 7 years of\nfollow-up and it was a marker of worse prognosis.13 The\nrisk of surgery for CD and UC can be up to 46.6% and 15.6%\n10 years after diagnosis, respectively, and has decreased\nsigni\ufb01cantly during the last 6 decades.14\nThe symptoms associated with IBD can be waxing and"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 0.0, "text": "mild disease with few symptoms to complicated disease\nwith strictures and \ufb01stulas. In a French population-based\nstudy\nof\nincident\nCD,\nthe\ncumulative\nprobability\nof\n*Authors share co-\ufb01rst authorship.\nAbbreviations used in this paper: ADA, adalimumab; AGA, American\nGastroenterological Association; CD, Crohn\u2019s disease; CDST, clinical\ndecision support tool; CI, con\ufb01dence interval; CRP, C-reactive protein;\nEEN, exclusive enteral nutrition; EIM, extraintestinal manifestation; FC,\nfecal calprotectin; HR, hazard ratio; IBD, in\ufb02ammatory bowel disease; ICR,\nileocolic resection; IFX, in\ufb02iximab; IMM, immunomodulator; IQR, inter-\nquartile range; MRI, magnetic resonance imaging; NUDT15, nudix hydro-\nlase; OR, odds ratio; SUCRA, surface under the cumulative ranking; TDM,\ntherapeutic drug monitoring; TPMT, thiopurine methyltransferase; TNFi,\ntumor necrosis factor inhibitor; UC, ulcerative colitis; UST, ustekinumab;\nVDZ, vedolizumab.\nMost current article\n\u00a9 2021 by the AGA Institute\n0016-5085/$36.00"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 4.0, "text": "Lofberg et al., 2012; Louis et al., 2018).\nVedolizumab may not represent the most appropriate biologic in\npresence of articular manifestations of IBD. Indeed, by virtue of its\nbinding to \u03b14\u03b27 integrin, this antibody may not impede the entry of\nproin\ufb02ammatory cells in joints. In fact, it may even contribute to higher\nin\ufb02ux of these cells to distant sites, as suggested by Diaz et al., who\nobserved de novo extraintestinal manifestations in vedolizumab-treated\nIBD patients (Diaz et al., 2020). An increased incidence of extra-\nintestinal manifestation in vedolizumab treated IBD patients have also\nbeen observed, compared to anti-TNF agents in a large American claims\ndatabase (Dubinsky et al., 2018). However, by improving disease activity\nthese drugs could still have an indirect impact on associated EIM, mostly\nperipheral arthritis, as suggested by the recent EMOTIVE retrospective\nanalysis (Kopylov et al., 2021). Ustekinumab, however, has also limited"}]}, {"question": "70 year old female with newly diagnosed severe UC\n", "answer": "[\n{\n\"drug_name\": \"Infliximab\",\n\"advantages\": \"Infliximab is a potent anti-inflammatory drug that can rapidly induce remission in severe UC. It is generally well-tolerated and can be used in elderly patients. It has been shown to reduce hospitalizations and the need for surgery.\",\n\"disadvantages\": \"Infliximab can cause serious side effects including infections, allergic reactions, and potentially an increased risk of malignancies. It requires intravenous administration and regular monitoring. The risk of side effects may be higher in elderly patients due to comorbidities and concomitant medications.\"\n},\n{\n\"drug_name\": \"Vedolizumab\",\n\"advantages\": \"Vedolizumab is a gut-selective immunosuppressant, meaning it specifically targets inflammation in the gut, potentially reducing systemic side effects. It has been shown to be effective in inducing and maintaining remission in UC.\",\n\"disadvantages\": \"Vedolizumab may take longer to work than other biologics, which may not be suitable for a patient with severe UC. It also requires intravenous administration and regular monitoring. The safety and efficacy in elderly patients is less well-studied than in younger patients.\"\n}\n]", "sources": [{"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2.0, "text": "Numerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated\nwith an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD\ncompared to the general pediatric population.46 Similar to\nthe youngest patients with IBD, elderly-onset IBD (diag-\nnosed at 60\u201365 years of age) has con\ufb02icting evidence on\nprognosis, with 1 study reporting fewer hospitalizations and\nless frequent requirement of immunosuppression in pa-"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2.0, "text": "Therefore, a consideration of risks, bene\ufb01ts, and alternatives\nis key to develop an individualized therapeutic plan for the\ninformed patient.\nIt is important to differentiate between disease activity\nand severity. Although the former refers to the burden of\nin\ufb02ammation at any given point in time, the latter takes into\naccount the disease phenotype and course, and is helpful in\ndetermining\nprognosis\nand\npredicting\ncomplications\n(Figure 1). For example, a patient with low disease activity\n(little to no symptoms and low in\ufb02ammatory markers) may\nactually have high severity (due to disease history or\nbehavior) increasing the risk for disease progression, and\nshould be managed more proactively and aggressively. We\nwill review predictors of IBD severity and activity.\nAge of In\ufb02ammatory Bowel Disease Diagnosis\nNumerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 1.0, "text": "de\ufb01ciencies, altered eating habits, in\ufb02ammatory cytokines,\nand corticosteroid use. Marked growth impairment at\ndiagnosis, de\ufb01ned as a height z-score < \u20132.5, is a poor\nprognostic sign.31 Furthermore, IBD patients exhibit \u201ccatch\nup\u201d growth beyond the typically expected age for growth\nplate closure (median additional years to reach adult height:\nmale patients with CD, 1.9 years and male patients with UC,\n2.5 years; female patients with CD: 2.6 years and female\npatients with UC, 2.8 years), suggesting that achieving\nremission even after reaching adolescence may allow for\nmaximal growth potential.18\nEarly Management Can Alter Disease Course and\nPrevent Complications\nData have consistently demonstrated that long-term IBD\ncomplications are mitigated by early treatment and remis-\nsion. In the long-term follow-up data from the CALM trial,\npatients with early CD who achieved deep remission,\ncompared to those who did not, had a signi\ufb01cantly lower"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 1.0, "text": "perianal CD varied between 11% and 19% at 1\u201310 years\nafter diagnosis.9 In a study of 983 patients with CD in Asia,\nstricturing or penetrating CD occurred in 41% and perianal\ndisease in 25% of patients.10 At the other end of the spec-\ntrum, incidental terminal ileitis can be diagnosed in 1.6% of\nindividuals undergoing nondiagnostic colonoscopy, with an\nuncertain but likely low rate of progression to overt CD.11\nWith respect to UC, most patients have mild to moderate\nseverity and 10%\u201315% of patients can experience a severe\ncourse.12 In a population-based cohort study, proctosigmoid\nlocation of colitis occurred in 73% of patients; of these,\ndisease extension occurred in 23% of patients at 7 years of\nfollow-up and it was a marker of worse prognosis.13 The\nrisk of surgery for CD and UC can be up to 46.6% and 15.6%\n10 years after diagnosis, respectively, and has decreased\nsigni\ufb01cantly during the last 6 decades.14\nThe symptoms associated with IBD can be waxing and"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2.0, "text": "associated with improved long-term outcomes.33 Data on\nthe impact of early therapy in UC are more limited, but, as\nUC is also a progressive disease with risk of colorectal\ncancer, surgery, and loss of colonic function, it is reasonable\nto treat early to mitigate these risks.\nHow to Diagnose In\ufb02ammatory Bowel Disease\nEarly\nIBD is heterogenous with wide variation in presentation.\nDisease activity at presentation can range from mild to severe\nand, as discussed, symptoms may be mild to none. These can\nmake the IBD diagnosis challenging, especially at a primary\ncare level. Danese et al34 have proposed a Red Flags Index\nconsisting of a 21-item questionnaire to help providers triage\nand identify patients with concerning symptoms in a timely\nmanner and refer to specialists appropriately. A useful adjunct\nto symptom-based criteria is fecal calprotectin (FC), a stool\nmarker of in\ufb02ammation; in a large meta-analysis, FC \ufffd 40 mg/\ng carried a \ufffd1% probability of IBD, effectively excluding the"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 1.0, "text": "10 years after diagnosis, respectively, and has decreased\nsigni\ufb01cantly during the last 6 decades.14\nThe symptoms associated with IBD can be waxing and\nwaning, but the underlying systemic in\ufb02ammation can lead\nto progressive, cumulative, and often irreversible intestinal\ndamage\nand\nrisk\nof\ncomplications\nif\nnot\ntreated\nadequately.15\nComplications\nassociated\nwith\nongoing\nin\ufb02ammation in CD include strictures, obstructions, \ufb01stulas,\nabscesses, and surgery,3,16 and those associated with UC\ninclude loss of colonic and anorectal function, surgery, and\ncolorectal cancer.2,4,17 Other complications include anemia,\nnutritional de\ufb01ciencies, loss of bone density, and progres-\nsive loss of quality of life. In children, persistent in\ufb02amma-\ntion\nis\nassociated\nwith\ngrowth\nimpairment,\nrisking\npermanent loss of height.18 Similar to other chronic dis-\neases, such as rheumatoid arthritis, the concept of cumula-\ntive damage is now acknowledged in IBD and can be"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2.0, "text": "of\nGastro-\nenterology.37\u201340\nRisk Strati\ufb01cation and Prognostication\nat Diagnosis\nAppropriately\nrisk-stratifying\nprognosis\nin\npatients\nrecently diagnosed with IBD is essential to inform selection\nof the most appropriate treatment and monitoring strate-\ngies. CD and UC phenotype and disease activity at initial\npresentation can vary widely from limited and mild to\nextensive and complicated. Certain baseline clinical features\nare associated with a more aggressive disease course with\nhigher risk of progression and complications. In higher-risk\npatients, early control of in\ufb02ammation with immune-\nmodifying therapies is critical. However, immunosuppres-\nsive therapies are associated with safety concerns in the\nshort- and long-term, and entail signi\ufb01cant health care costs.\nTherefore, a consideration of risks, bene\ufb01ts, and alternatives\nis key to develop an individualized therapeutic plan for the\ninformed patient.\nIt is important to differentiate between disease activity"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7.0, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 3.0, "text": "hospitalization (HR, 1.01; 95% CI, 1.00\u20131.01).16 Ileal and\nupper gastrointestinal disease location and extensive dis-\nease are also markers of severe disease.61 Cigarette smoking\nis associated with complications and need for therapy\nescalation.61\nIn CD, the threshold of suspicion should be low for high-\nquality imaging of the pelvis, such as MRI, to rule our\nperianal CD. In a retrospective study of 136 pediatric CD\npatients, presence of anal \ufb01ssures and skin tags, non-White\nrace, and elevated C-reactive protein (CRP) were risk factors\nfor perianal CD.62 In another study of 274 patients in China\nwith recently diagnosed CD, all of whom underwent MRI\npelvis, asymptomatic perianal \ufb01stulas were diagnosed in\n17.5% of patients and colonic location of CD was a risk\nfactor for asymptomatic perianal \ufb01stulas.63\nIn UC, corresponding predictors of aggressive disease\nadvised by the International Organization for the Study of\nIn\ufb02ammatory Bowel Disease include active colonic ulcers"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2.0, "text": "nosed at 60\u201365 years of age) has con\ufb02icting evidence on\nprognosis, with 1 study reporting fewer hospitalizations and\nless frequent requirement of immunosuppression in pa-\ntients diagnosed after age 60 years,47 and a meta-analysis\nsuggested\nthat,\nalthough\nelderly\nIBD\npresents\nless\ncommonly with complications, there are similar or higher\nrates of surgery compared to a nonelderly population.48 It is\nbeing increasingly recognized that frailty, rather than\nchronologic age, may be the driver of adverse outcomes in\nthis group.49,50\nOther Demographic Variables\nThere are signi\ufb01cant differences in IBD phenotype\nand outcomes based on race and ethnicity, likely due to\na multitude of factors, both social and biologic. Emer-\ngency department use, hospitalization, complicated dis-\nease\ncourse,\nand\nIBD-related\ndisability\nare\nmore\ncommon in minority and lower socioeconomic status\ngroups.51,52 In a study of 770 patients with IBD, South\nAsian immigrants living in the United Kingdom were\nmore\nlikely\nto"}]}, {"question": "35 year old male with known moderate UC with prior exposure to infliximab but has worsening colitis on endoscopy despite compliance\n", "answer": "Based on the patient's profile, the patient has moderate ulcerative colitis and has been previously treated with infliximab but is not responding well as his condition is worsening. \n\nGiven this information, the top two choices of biological drugs for this patient would be Ustekinumab and Tofacitinib. These drugs are ranked highest in patients with prior exposure to TNF antagonists like infliximab.\n\nHere are the pros and cons of these two drugs:\n\n1. Ustekinumab:\n   - Advantages: Ustekinumab is ranked highest for inducing remission and endoscopic improvement in patients with prior exposure to TNF antagonists. It also has a lower risk of infections compared to other drugs.\n   - Disadvantages: The main disadvantage of Ustekinumab is that it may not be as effective in patients who have had prior exposure to other biologic therapies.\n\n2. Tofacitinib:\n   - Advantages: Tofacitinib is also ranked highly for inducing remission and endoscopic improvement in patients with prior exposure to TNF antagonists. \n   - Disadvantages: Tofacitinib may have a higher risk of infections compared to other drugs. It also may not be as effective in patients who have had prior exposure to other biologic therapies.\n\nHere is the output in JSON format:\n\n[\n  {\n    \"drug_name\": \"Ustekinumab\",\n    \"advantages\": \"Ranked highest for inducing remission and endoscopic improvement in patients with prior exposure to TNF antagonists. Lower risk of infections compared to other drugs.\",\n    \"disadvantages\": \"May not be as effective in patients who have had prior exposure to other biologic therapies.\"\n  },\n  {\n    \"drug_name\": \"Tofacitinib\",\n    \"advantages\": \"Ranked highly for inducing remission and endoscopic improvement in patients with prior exposure to TNF antagonists.\",\n    \"disadvantages\": \"Higher risk of infections compared to other drugs. May not be as effective in patients who have had prior exposure to other biologic therapies.\"\n  }\n]", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 6.0, "text": "were signi\ufb01cantly different (Table 2). Overall, in\ufb02iximab\n(SUCRA, 0.95) was ranked highest for inducing clinical\nremission\nin\nbiologic-na\u00efve\npatients\nwith\nmoderate\u2013severe UC (Figure 2A). With an estimated\nplacebo rate of achieving remission of 10% in included\ntrials, we anticipate that 31.1%, 17.7%, 23.7%, 22.0%,\nFigure 2. (A) Relative ef\ufb01-\ncacy\nof\ndifferent\nin-\nterventions for induction of\nclinical\nremission\nand\nendoscopic\nimprovement\nin biologic-na\u00efve patients\nwith moderate to severely\nactive ulcerative colitis. (B)\nRelative\nef\ufb01cacy\nof\ndifferent interventions for\ninduction of clinical remis-\nsion\nand\nendoscopic\nimprovement\nin\npatients\nwith moderate to severely\nactive\nulcerative\ncolitis\nwith prior exposure to tu-\nmor necrosis factor (TNF)\u237a\nantagonists. SUCRA, sur-\nface under the cumulative\nranking.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2185"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "vs adalimumab: OR, 11.05; 95% CI, 1.79\u201368.41; moderate CE). Vedolizumab had the lowest risk\nof infections (SUCRA, 0.81), followed by ustekinumab (SUCRA, 0.63) in maintenance trials.\nCONCLUSIONS:\nIn a systematic review and network meta-analysis, we found in\ufb02iximab to be ranked highest in\nbiologic-na\u00efve patients, and ustekinumab and tofacitinib were ranked highest in patients with\nprior exposure to TNF antagonists, for induction of remission and endoscopic improvement in\npatients with moderate to severe ulcerative colitis. More trials of direct comparisons are\nneeded to inform clinical decision making with greater con\ufb01dence.\nKeywords: GRADE; Pharmacotherapy; In\ufb02ammatory Bowel Disease; UC; Comparative Ef\ufb01cacy.\nU\nlcerative colitis affects 1 in 200 to 1 in 400 people\nin Western nations, and its global incidence and\nprevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "in induction trials, we estimated that 58.7%, 40.4%,\n42.7%, 51.9%, 46.5%, and 44.4% of in\ufb02iximab-, adali-\nmumab-, golimumab-, vedolizumab-, tofacitinib-, and\nustekinumab-treated patients, respectively, would ach-\nieve induction of endoscopic improvement.\nSecond-line\npharmacotherapy\nfor\nmoderate\u2013severe\nulcerative colitis. Overall, 7 RCTs including 1580 pa-\ntients with moderate\u2013severe ulcerative colitis with prior\nexposure to TNFa antagonists were identi\ufb01ed. These\nincluded subgroup analyses of trials of adalimumab,21\nvedolizumab,24,25\ntofacitinib,26\nand\nustekinumab.7\nThere were no trials of in\ufb02iximab or golimumab in\npatients with prior exposure to TNFa antagonists who\nmet inclusion criteria. In trials of adalimumab, only pa-\ntients with loss of response or intolerance to a prior\nTNFa antagonist were included. In contrast, in trials of\nvedolizumab, 48% to 58% of patients had inadequate\nresponse to a TNFa antagonist, and in trials of usteki-"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 27.0, "text": "Burr et al. \n \n27 of 45 \nDISCUSSION \nWe conducted a contemporaneous systematic review and network meta-analysis of \nbiological therapies and small molecules for moderate to severely active UC. This has \nincorporated data from 28 RCTs and over 12,500 patients. Overall, in terms of clinical \nremission and clinical response at 6 to 14 weeks, upadacitinib 45mg o.d. ranked first in all \npatients, in patients previously exposed to anti-TNF-\u03b1 therapies, and in patients na\u00efve to these \ndrugs. In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \nupadacitinib 45mg o.d., and infliximab 5mg/kg. However, again upadacitinib 45mg o.d. \nranked first in patients previously exposed to anti-TNF-\u03b1 therapies, and in patients who were \nanti-TNF-\u03b1 na\u00efve. In terms of safety, upadacitinib 45mg o.d. ranked last for total number of \nadverse events, and ustekinumab 130mg first. However, none of the drugs studied were more"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "What You Need to Know\nBackground\nA systematic review and network meta-analysis is\nneeded to compare ef\ufb01cacy and safety of \ufb01rst-line\n(biologic-na\u00efve) and second-line (prior exposure to\ntumor necrosis factor [TNF] antagonists) agents for\ntreatment of moderate to severely active ulcerative\ncolitis.\nFindings\nIn\ufb02iximab was ranked highest in biologic-na\u00efve pa-\ntients, and ustekinumab and tofacitinib were ranked\nhighest in patients with prior exposure to TNF an-\ntagonists, for induction of remission and endoscopic\nimprovement. More trials of direct comparisons are\nneeded to inform clinical decision-making with\ngreater con\ufb01dence.\nImplications for patient care\nPatients with moderate to severely active ulcerative\ncolitis should receive in\ufb02iximab or vedolizumab as\n\ufb01rst-line therapy, or ustekinumab or tofacitinib if\nthey have prior exposure to TNF antagonists.\n2180 Singh et al\nClinical Gastroenterology and Hepatology Vol. 18, No. 10"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 9.0, "text": "(infliximab, adalimumab, or golimumab), anti-integrin antibodies (vedolizumab or \netrolizumab), or anti-interleukin-12/23 antibodies (ustekinumab)) or small molecules (janus \nkinase inhibitors (tofacitinib, filgotinib, or upadacitinib) or sphingosine-1-phosphate receptor \nmodulators (ozanimod)) at the doses taken through into testing in phase III clinical trials. \nStudies had to recruit ambulatory adults (\u226518 years) with moderate to severely active UC \n(Supplementary Table 1), and compared biological therapies or small molecules with \nplacebo, or with each other. We required a minimum follow-up duration of 6 weeks.  \nTwo investigators (NEB and ACF) conducted independent literature searches. We \nidentified studies on UC with the terms: inflammatory bowel disease, colitis, or ulcerative \ncolitis (both as medical subject headings and free text terms). We combined these using the \nset operator AND with studies identified with the following terms: infliximab, remicade,"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 30.0, "text": "use of newer small molecules is likely to have greater financial implications. Whether an \ninferior, but cheaper, drug should be used to treat moderate to severe UC is not the subject of \nthe current study. The results of this network meta-analysis could, however, be used to \ninform a cost-effectiveness analysis to help guide future treatment selection.  \nIn summary, this systematic review and network meta-analysis has demonstrated that \nall biological therapies and small molecules, other than adalimumab 160/160mg, adalimumab \n80/40mg, and filgotinib 100mg o.d. were superior to placebo for induction of remission of \nmoderate to severe UC, and all drugs, other than adalimumab 80/40mg, were superior to \nplacebo in terms of endoscopic improvement. Among biological therapies, infliximab ranked \nhighest for all endpoints in all patients, and in patients na\u00efve to anti-TNF-\u03b1 drugs, with \nustekinumab ranked highest for all endpoints in patients exposed to anti-TNF-\u03b1 therapy. In"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 29.0, "text": "Burr et al. \n \n29 of 45 \npreferential janus kinase-1 inhibitor, although given filgotinib also has increased selectivity \nfor janus kinase-1 this cannot be the sole reason for upadacitinib\u2019s higher ranking. Despite \nthese limitations, the results of our study are still useful for informing treatment decisions for \npatients with moderate to severely active UC and can be used in future updates of evidence-\nbased management guidelines.  \nAn initial network meta-analyses by Singh et al. demonstrated infliximab to be the \nmost efficacious drug for patients na\u00efve to biological therapies in terms of induction of \nclinical remission and endoscopic improvement, with vedolizumab ranked second.[22] In \npatients exposed to biological therapies tofacitinib ranked first for both clinical remission and \nendoscopic improvement. An update to this work from 2020, including data from head-to-\nhead trials of vedolizumab and adalimumab, as well as phase III placebo-controlled trials of"}]}, {"question": "60 year old female with newly diagnosed moderate UC with a background of congestive cardiac failure\n", "answer": "[\n{\n\"drug_name\": \"Vedolizumab\",\n\"advantages\": \"Vedolizumab is a gut-selective immunosuppressant, meaning it specifically targets the gut and has less systemic side effects. It has been shown to be effective in treating moderate to severe UC. It is also less likely to have cardiac side effects, which is beneficial for a patient with congestive cardiac failure.\",\n\"disadvantages\": \"Vedolizumab requires intravenous administration, which can be inconvenient. It may also take several weeks to see an effect. Side effects can include headache, joint pain, nausea, and fever. There is also a risk of serious infections.\"\n},\n{\n\"drug_name\": \"Ustekinumab\",\n\"advantages\": \"Ustekinumab is effective in treating moderate to severe UC and can be administered subcutaneously, which can be more convenient. It works by blocking certain proteins (interleukins 12 and 23) that can cause inflammation in the body.\",\n\"disadvantages\": \"Ustekinumab may increase the risk of infections. Side effects can include fatigue, headache, and skin rash. It may also take several weeks to see an effect. The impact on congestive cardiac failure is not well studied.\"\n}\n]", "sources": [{"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2.0, "text": "Numerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated\nwith an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD\ncompared to the general pediatric population.46 Similar to\nthe youngest patients with IBD, elderly-onset IBD (diag-\nnosed at 60\u201365 years of age) has con\ufb02icting evidence on\nprognosis, with 1 study reporting fewer hospitalizations and\nless frequent requirement of immunosuppression in pa-"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 1.0, "text": "de\ufb01ciencies, altered eating habits, in\ufb02ammatory cytokines,\nand corticosteroid use. Marked growth impairment at\ndiagnosis, de\ufb01ned as a height z-score < \u20132.5, is a poor\nprognostic sign.31 Furthermore, IBD patients exhibit \u201ccatch\nup\u201d growth beyond the typically expected age for growth\nplate closure (median additional years to reach adult height:\nmale patients with CD, 1.9 years and male patients with UC,\n2.5 years; female patients with CD: 2.6 years and female\npatients with UC, 2.8 years), suggesting that achieving\nremission even after reaching adolescence may allow for\nmaximal growth potential.18\nEarly Management Can Alter Disease Course and\nPrevent Complications\nData have consistently demonstrated that long-term IBD\ncomplications are mitigated by early treatment and remis-\nsion. In the long-term follow-up data from the CALM trial,\npatients with early CD who achieved deep remission,\ncompared to those who did not, had a signi\ufb01cantly lower"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2.0, "text": "Therefore, a consideration of risks, bene\ufb01ts, and alternatives\nis key to develop an individualized therapeutic plan for the\ninformed patient.\nIt is important to differentiate between disease activity\nand severity. Although the former refers to the burden of\nin\ufb02ammation at any given point in time, the latter takes into\naccount the disease phenotype and course, and is helpful in\ndetermining\nprognosis\nand\npredicting\ncomplications\n(Figure 1). For example, a patient with low disease activity\n(little to no symptoms and low in\ufb02ammatory markers) may\nactually have high severity (due to disease history or\nbehavior) increasing the risk for disease progression, and\nshould be managed more proactively and aggressively. We\nwill review predictors of IBD severity and activity.\nAge of In\ufb02ammatory Bowel Disease Diagnosis\nNumerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2.0, "text": "nosed at 60\u201365 years of age) has con\ufb02icting evidence on\nprognosis, with 1 study reporting fewer hospitalizations and\nless frequent requirement of immunosuppression in pa-\ntients diagnosed after age 60 years,47 and a meta-analysis\nsuggested\nthat,\nalthough\nelderly\nIBD\npresents\nless\ncommonly with complications, there are similar or higher\nrates of surgery compared to a nonelderly population.48 It is\nbeing increasingly recognized that frailty, rather than\nchronologic age, may be the driver of adverse outcomes in\nthis group.49,50\nOther Demographic Variables\nThere are signi\ufb01cant differences in IBD phenotype\nand outcomes based on race and ethnicity, likely due to\na multitude of factors, both social and biologic. Emer-\ngency department use, hospitalization, complicated dis-\nease\ncourse,\nand\nIBD-related\ndisability\nare\nmore\ncommon in minority and lower socioeconomic status\ngroups.51,52 In a study of 770 patients with IBD, South\nAsian immigrants living in the United Kingdom were\nmore\nlikely\nto"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 1.0, "text": "perianal CD varied between 11% and 19% at 1\u201310 years\nafter diagnosis.9 In a study of 983 patients with CD in Asia,\nstricturing or penetrating CD occurred in 41% and perianal\ndisease in 25% of patients.10 At the other end of the spec-\ntrum, incidental terminal ileitis can be diagnosed in 1.6% of\nindividuals undergoing nondiagnostic colonoscopy, with an\nuncertain but likely low rate of progression to overt CD.11\nWith respect to UC, most patients have mild to moderate\nseverity and 10%\u201315% of patients can experience a severe\ncourse.12 In a population-based cohort study, proctosigmoid\nlocation of colitis occurred in 73% of patients; of these,\ndisease extension occurred in 23% of patients at 7 years of\nfollow-up and it was a marker of worse prognosis.13 The\nrisk of surgery for CD and UC can be up to 46.6% and 15.6%\n10 years after diagnosis, respectively, and has decreased\nsigni\ufb01cantly during the last 6 decades.14\nThe symptoms associated with IBD can be waxing and"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 1.0, "text": "10 years after diagnosis, respectively, and has decreased\nsigni\ufb01cantly during the last 6 decades.14\nThe symptoms associated with IBD can be waxing and\nwaning, but the underlying systemic in\ufb02ammation can lead\nto progressive, cumulative, and often irreversible intestinal\ndamage\nand\nrisk\nof\ncomplications\nif\nnot\ntreated\nadequately.15\nComplications\nassociated\nwith\nongoing\nin\ufb02ammation in CD include strictures, obstructions, \ufb01stulas,\nabscesses, and surgery,3,16 and those associated with UC\ninclude loss of colonic and anorectal function, surgery, and\ncolorectal cancer.2,4,17 Other complications include anemia,\nnutritional de\ufb01ciencies, loss of bone density, and progres-\nsive loss of quality of life. In children, persistent in\ufb02amma-\ntion\nis\nassociated\nwith\ngrowth\nimpairment,\nrisking\npermanent loss of height.18 Similar to other chronic dis-\neases, such as rheumatoid arthritis, the concept of cumula-\ntive damage is now acknowledged in IBD and can be"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 3.0, "text": "Disease Phenotype and Clinical Characteristics\nThe International Organization for the Study of In\ufb02am-\nmatory Bowel Disease and the American Gastroenterological\nAssociation (AGA) provide a framework for categorization of\nCD and UC severity into mild-, moderate-, and high-risk\ngroups based on phenotype and other characteristics.59,60\nIn CD, the presence of large or deep mucosal lesions on\nendoscopy or magnetic resonance imaging (MRI), history of\na \ufb01stula, abscess, or intestinal resection are predictors of\nworse outcomes.59,60 In a prospective population-based\ninception cohort of 213 patients with CD, penetrating\nbehavior was associated with a higher risk of progression to\nperianal disease (HR, 5.65; 95% CI, 2.65\u201312.03) and was a\nrisk factor for resection (HR, 3.92; 95% CI, 1.86\u20138.67) and\nhospitalization (HR, 1.01; 95% CI, 1.00\u20131.01).16 Ileal and\nupper gastrointestinal disease location and extensive dis-\nease are also markers of severe disease.61 Cigarette smoking"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7.0, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2.0, "text": "of\nGastro-\nenterology.37\u201340\nRisk Strati\ufb01cation and Prognostication\nat Diagnosis\nAppropriately\nrisk-stratifying\nprognosis\nin\npatients\nrecently diagnosed with IBD is essential to inform selection\nof the most appropriate treatment and monitoring strate-\ngies. CD and UC phenotype and disease activity at initial\npresentation can vary widely from limited and mild to\nextensive and complicated. Certain baseline clinical features\nare associated with a more aggressive disease course with\nhigher risk of progression and complications. In higher-risk\npatients, early control of in\ufb02ammation with immune-\nmodifying therapies is critical. However, immunosuppres-\nsive therapies are associated with safety concerns in the\nshort- and long-term, and entail signi\ufb01cant health care costs.\nTherefore, a consideration of risks, bene\ufb01ts, and alternatives\nis key to develop an individualized therapeutic plan for the\ninformed patient.\nIt is important to differentiate between disease activity"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 29.0, "text": "potentially more efficacious for moderate to severely active UC than existing licensed \ntherapies. \nOur results confirm that all available drugs, other than adalimumab 160/160mg, \nadalimumab 80/40mg, and filgotinib 100mg o.d. were more efficacious than placebo for the \ntreatment of moderate to severe UC, across all endpoints studied at 6 to 14 weeks. All drugs \nwere safe and well-tolerated, with no significant increase in serious adverse events or adverse \nevents leading to withdrawal over the rates seen in the placebo arms, although the RR of"}]}, {"question": "38 year old female with newly diagnosed moderate UC and psoriasis\n", "answer": "[\n{\n\"drug_name\": \"Ustekinumab\",\n\"advantages\": \"Ustekinumab is a good choice for this patient as it is effective in treating both ulcerative colitis and psoriasis. It is also suitable for patients who are newly diagnosed.\",\n\"disadvantages\": \"Potential side effects of Ustekinumab include respiratory infections, fatigue, headache, and skin rash. It may also increase the risk of certain types of cancer.\"\n},\n{\n\"drug_name\": \"Vedolizumab\",\n\"advantages\": \"Vedolizumab is effective in treating moderate to severe ulcerative colitis. It is a gut-selective medication, meaning it specifically targets the gut and does not have systemic effects.\",\n\"disadvantages\": \"Vedolizumab may not be as effective in treating psoriasis. Common side effects include headache, joint pain, nausea, and fever. Serious side effects can include infections and liver problems.\"\n}\n]", "sources": [{"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2.0, "text": "Numerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated\nwith an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD\ncompared to the general pediatric population.46 Similar to\nthe youngest patients with IBD, elderly-onset IBD (diag-\nnosed at 60\u201365 years of age) has con\ufb02icting evidence on\nprognosis, with 1 study reporting fewer hospitalizations and\nless frequent requirement of immunosuppression in pa-"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 1.0, "text": "de\ufb01ciencies, altered eating habits, in\ufb02ammatory cytokines,\nand corticosteroid use. Marked growth impairment at\ndiagnosis, de\ufb01ned as a height z-score < \u20132.5, is a poor\nprognostic sign.31 Furthermore, IBD patients exhibit \u201ccatch\nup\u201d growth beyond the typically expected age for growth\nplate closure (median additional years to reach adult height:\nmale patients with CD, 1.9 years and male patients with UC,\n2.5 years; female patients with CD: 2.6 years and female\npatients with UC, 2.8 years), suggesting that achieving\nremission even after reaching adolescence may allow for\nmaximal growth potential.18\nEarly Management Can Alter Disease Course and\nPrevent Complications\nData have consistently demonstrated that long-term IBD\ncomplications are mitigated by early treatment and remis-\nsion. In the long-term follow-up data from the CALM trial,\npatients with early CD who achieved deep remission,\ncompared to those who did not, had a signi\ufb01cantly lower"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2.0, "text": "Therefore, a consideration of risks, bene\ufb01ts, and alternatives\nis key to develop an individualized therapeutic plan for the\ninformed patient.\nIt is important to differentiate between disease activity\nand severity. Although the former refers to the burden of\nin\ufb02ammation at any given point in time, the latter takes into\naccount the disease phenotype and course, and is helpful in\ndetermining\nprognosis\nand\npredicting\ncomplications\n(Figure 1). For example, a patient with low disease activity\n(little to no symptoms and low in\ufb02ammatory markers) may\nactually have high severity (due to disease history or\nbehavior) increasing the risk for disease progression, and\nshould be managed more proactively and aggressively. We\nwill review predictors of IBD severity and activity.\nAge of In\ufb02ammatory Bowel Disease Diagnosis\nNumerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 1.0, "text": "perianal CD varied between 11% and 19% at 1\u201310 years\nafter diagnosis.9 In a study of 983 patients with CD in Asia,\nstricturing or penetrating CD occurred in 41% and perianal\ndisease in 25% of patients.10 At the other end of the spec-\ntrum, incidental terminal ileitis can be diagnosed in 1.6% of\nindividuals undergoing nondiagnostic colonoscopy, with an\nuncertain but likely low rate of progression to overt CD.11\nWith respect to UC, most patients have mild to moderate\nseverity and 10%\u201315% of patients can experience a severe\ncourse.12 In a population-based cohort study, proctosigmoid\nlocation of colitis occurred in 73% of patients; of these,\ndisease extension occurred in 23% of patients at 7 years of\nfollow-up and it was a marker of worse prognosis.13 The\nrisk of surgery for CD and UC can be up to 46.6% and 15.6%\n10 years after diagnosis, respectively, and has decreased\nsigni\ufb01cantly during the last 6 decades.14\nThe symptoms associated with IBD can be waxing and"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 3.0, "text": "In UC, corresponding predictors of aggressive disease\nadvised by the International Organization for the Study of\nIn\ufb02ammatory Bowel Disease include active colonic ulcers\nand prior use of biologics.59 Extensive colitis, deep ulcers,\nneed for corticosteroids, hospitalization, Clostridium dif\ufb01cile,\nand cytomegalovirus infection also indicate higher colec-\ntomy risk.64 Of note, disease extension from limited disease\nto\nextensive\nor\npancolitis\nis\nassociated\nwith\nworse\nprognosis.45,65\nIn addition, co-occurrence of other immune-mediated\nin\ufb02ammatory diseases can occur, most commonly with\npsoriasis and asthma, but also, in more rare instances, with\nother gastrointestinal diseases (eg, celiac, nonalcoholic fatty\nliver disease,66 and eosinophilic esophagitis).67,68 Presence\nof a concomitant immune-mediated in\ufb02ammatory disease is\nFigure\n1. In\ufb02ammatory\nbowel disease severity vs\ndisease activity variables.\nASCA, anti-Saccharomyces\ncerevisiae\nantibodies;\nANCA,\nanti-neutrophil\ncytoplasmic\nantibodies;"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2.0, "text": "of\nGastro-\nenterology.37\u201340\nRisk Strati\ufb01cation and Prognostication\nat Diagnosis\nAppropriately\nrisk-stratifying\nprognosis\nin\npatients\nrecently diagnosed with IBD is essential to inform selection\nof the most appropriate treatment and monitoring strate-\ngies. CD and UC phenotype and disease activity at initial\npresentation can vary widely from limited and mild to\nextensive and complicated. Certain baseline clinical features\nare associated with a more aggressive disease course with\nhigher risk of progression and complications. In higher-risk\npatients, early control of in\ufb02ammation with immune-\nmodifying therapies is critical. However, immunosuppres-\nsive therapies are associated with safety concerns in the\nshort- and long-term, and entail signi\ufb01cant health care costs.\nTherefore, a consideration of risks, bene\ufb01ts, and alternatives\nis key to develop an individualized therapeutic plan for the\ninformed patient.\nIt is important to differentiate between disease activity"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A Users Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 7.0, "text": "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n\nRisk stratification: Mild\nClinical features: NA\nTreatment options: 5-ASA (oral and/or topical)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: VDZ or UST\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Thiopurine\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Psoriasis or psoriatic arthritis\nTreatment options: UST\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Other arthritis\nTreatment options: TNFi\n\n"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2.0, "text": "nosed at 60\u201365 years of age) has con\ufb02icting evidence on\nprognosis, with 1 study reporting fewer hospitalizations and\nless frequent requirement of immunosuppression in pa-\ntients diagnosed after age 60 years,47 and a meta-analysis\nsuggested\nthat,\nalthough\nelderly\nIBD\npresents\nless\ncommonly with complications, there are similar or higher\nrates of surgery compared to a nonelderly population.48 It is\nbeing increasingly recognized that frailty, rather than\nchronologic age, may be the driver of adverse outcomes in\nthis group.49,50\nOther Demographic Variables\nThere are signi\ufb01cant differences in IBD phenotype\nand outcomes based on race and ethnicity, likely due to\na multitude of factors, both social and biologic. Emer-\ngency department use, hospitalization, complicated dis-\nease\ncourse,\nand\nIBD-related\ndisability\nare\nmore\ncommon in minority and lower socioeconomic status\ngroups.51,52 In a study of 770 patients with IBD, South\nAsian immigrants living in the United Kingdom were\nmore\nlikely\nto"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 1.0, "text": "10 years after diagnosis, respectively, and has decreased\nsigni\ufb01cantly during the last 6 decades.14\nThe symptoms associated with IBD can be waxing and\nwaning, but the underlying systemic in\ufb02ammation can lead\nto progressive, cumulative, and often irreversible intestinal\ndamage\nand\nrisk\nof\ncomplications\nif\nnot\ntreated\nadequately.15\nComplications\nassociated\nwith\nongoing\nin\ufb02ammation in CD include strictures, obstructions, \ufb01stulas,\nabscesses, and surgery,3,16 and those associated with UC\ninclude loss of colonic and anorectal function, surgery, and\ncolorectal cancer.2,4,17 Other complications include anemia,\nnutritional de\ufb01ciencies, loss of bone density, and progres-\nsive loss of quality of life. In children, persistent in\ufb02amma-\ntion\nis\nassociated\nwith\ngrowth\nimpairment,\nrisking\npermanent loss of height.18 Similar to other chronic dis-\neases, such as rheumatoid arthritis, the concept of cumula-\ntive damage is now acknowledged in IBD and can be"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 3.0, "text": "stage, there is little data on the impact of BMI on the response to vedo-\nlizumab or ustekinumab in IBD, but response to the second was lower in a\nstudy of obese patients with psoriasis (Pirro et al., 2021).\nSarcopenia, often associated with malnutrition, has an important\nimpact in IBD patients on quality of life, prognosis, outcome of surgical\nTable 2\nEf\ufb01cacy of biological treatments according to the line of treatment, earlier exposure, disease phenotype and patient characteristics.\nP. Juillerat et al.\nCurrent Research in Pharmacology and Drug Discovery 3 (2022) 100104\n4"}]}, {"question": "25 year old pregnant woman with severe distal ulcerative colitis\n", "answer": "I don't know", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "", "filename": "otad009.pdf", "page": 0.0, "text": "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\nReceived for publication: September 21, 2022. Editorial Decision: January 25, 2023\n \nDownloaded from https://academic.oup.com/crohnscolitis360/article/5/2/otad009/7066911 by National University of Singapore user on 23 May 2023"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7.0, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2.0, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "", "filename": "otad009.pdf", "page": 0.0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}]}, {"question": "56 year old man with moderate to severe ulcerative colitis and ankylosing spondylitis\n", "answer": "I'm sorry, but I can't provide the help you're looking for.", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "", "filename": "otad009.pdf", "page": 0.0, "text": "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\nReceived for publication: September 21, 2022. Editorial Decision: January 25, 2023\n \nDownloaded from https://academic.oup.com/crohnscolitis360/article/5/2/otad009/7066911 by National University of Singapore user on 23 May 2023"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "meta-analysis. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2022.07.032 \n(2022).\n5. \nBurr, N. E. et al. Efficacy of biological therapies and small molecules in moderate to  \nsevere ulcerative colitis: systematic review and network meta-analysis. Gut 71, 1976\u20131987 \n(2022).\n6. Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid \narthritis. N. Engl. J. Med. 386, 316\u2013326 (2022).\n7. \nBiasci, D. et al. A blood-based prognostic biomarker in IBD. Gut 68, 1386\u20131395 (2019).\n8. Verstockt, B., Parkes, M. & Lee, J. C. How do we predict a patient\u2019s disease course and \nwhether they will respond to specific treatments? Gastroenterology 162, 1383\u20131395 \n(2022).\n9. \nSazonovs, A. et al. HLA-DQA1*05 carriage associated with development of anti-\ndrug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease. \nGastroenterology 158, 189\u2013199 (2020).\n10. Nguyen, N. H., Singh, S. & Sandborn, W. J. Positioning therapies in the management"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7.0, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2.0, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}]}, {"question": "38 year old man with severe ulcerative colitis and has lost response to vedolizumab\n", "answer": "[{\"drug_name\": \"Ustekinumab\", \"advantages\": \"Ustekinumab has shown efficacy in inducing remission in patients who have lost response to other treatments such as vedolizumab. It also has a superior safety profile which may be attractive for patients.\", \"disadvantages\": \"The limitations of ustekinumab include limited efficacy in some patients, primary non-response, secondary loss of response, and immunogenicity.\"}, {\"drug_name\": \"Tofacitinib\", \"advantages\": \"Tofacitinib has been shown to be effective in inducing remission in patients who have lost response to other treatments. It is also an oral medication, which may be preferred by some patients.\", \"disadvantages\": \"Tofacitinib has been associated with an increased risk of venous thromboembolism. Other limitations include limited efficacy in some patients, primary non-response, secondary loss of response, and immunogenicity.\"}]", "sources": [{"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "and corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis, \nnamely vedolizumab and, more recently, usteki numab. \nHowever, \ntreatment \nwith \nbiologics \nhas \nseveral \nlimit ations, including limited efficacy, primary non-\nresponse, secondary loss of response, immunogenicity,"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "in induction trials, we estimated that 58.7%, 40.4%,\n42.7%, 51.9%, 46.5%, and 44.4% of in\ufb02iximab-, adali-\nmumab-, golimumab-, vedolizumab-, tofacitinib-, and\nustekinumab-treated patients, respectively, would ach-\nieve induction of endoscopic improvement.\nSecond-line\npharmacotherapy\nfor\nmoderate\u2013severe\nulcerative colitis. Overall, 7 RCTs including 1580 pa-\ntients with moderate\u2013severe ulcerative colitis with prior\nexposure to TNFa antagonists were identi\ufb01ed. These\nincluded subgroup analyses of trials of adalimumab,21\nvedolizumab,24,25\ntofacitinib,26\nand\nustekinumab.7\nThere were no trials of in\ufb02iximab or golimumab in\npatients with prior exposure to TNFa antagonists who\nmet inclusion criteria. In trials of adalimumab, only pa-\ntients with loss of response or intolerance to a prior\nTNFa antagonist were included. In contrast, in trials of\nvedolizumab, 48% to 58% of patients had inadequate\nresponse to a TNFa antagonist, and in trials of usteki-"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 11.0, "text": "should be discussed adequately with patients.\nIntegrating \ufb01ndings from this meta-analysis and other\nstudies, current evidence favors in\ufb02iximab or vedolizu-\nmab\nas\nthe\npreferred\n\ufb01rst-line\nagents\nfor\nmoderate\u2013severe ulcerative colitis. In patients who fail\nin\ufb02iximab, ustekinumab and tofacitinib likely would be\nmost ef\ufb01cacious, and ustekinumab\u2019s superior safety\npro\ufb01le may be attractive in light of recent concerns\naround\nvenous\nthromboembolism\nwith\ntofacitinib.\nHowever, besides quality of evidence, several other fac-\ntors including a balance of risk\u2013bene\ufb01t pro\ufb01le, speci\ufb01c\npatient attributes (age, comorbid conditions including\nrheumatic or dermatologic diseases, and so forth), clin-\nical judgment and experience of the treating physicians,\nvalues\nand\npreferences\nof\npatients\n(dosing\nroute,\nregimen, acceptability of risk\u2013bene\ufb01t trade-offs, and so\nforth), as well as the costs/resources available, are\nimportant to facilitate shared decision making, in devel-"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:\nWe searched publication databases through September 30, 2019, for randomized trials of\nadults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\ntofacitinib, or ustekinumab, as \ufb01rst-line or second-line agents, compared with placebo or\nanother active agent. Ef\ufb01cacy outcomes were induction and maintenance of remission and\nendoscopic improvement; safety outcomes were serious adverse events and infections. We\nperformed a \ufb01xed-effects network meta-analysis using the frequentist approach, and calculated\nodds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\nranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\nRecommendations, Assessment, Development and Evaluation).\nRESULTS:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "patients with moderate\u2013severe ulcerative colitis with\nprior exposure to TNFa antagonists (Figure 2B). With an\nestimated placebo rate of achieving clinical remission of\n3% in included trials, we estimated that 3.2%, 5.6%,\n26.9%, and 26.3% of adalimumab-, vedolizumab-, tofaci-\ntinib-, and ustekinumab-treated patients, respectively,\nwould achieve induction of remission.\nInduction of endoscopic improvement. On direct meta-\nanalysis, tofacitinib and ustekinumab, but not vedolizumab\nor adalimumab, were superior to placebo for induction of\nendoscopic improvement, with minimal heterogeneity\nTable 3. Comparative Ef\ufb01cacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in\nPatients With Moderate\u2013Severe Ulcerative Colitis With Prior Exposure to Tumor Necrosis Factor-a Antagonists Using\nNetwork Meta-Analysis\nInduction of clinical remission\nInduction of endoscopic\nimprovement\nUstekinumab 6 mg/kg\n0.97 (0.11\u20138.72)\n5.99 (1.13\u201331.76)\n10.71 (2.01\u201357.20)"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 1.0, "text": "armamentarium, and a paucity of direct comparisons, \ndrug positioning is a clinical challenge. Several network \nmeta-analyses have compared the therapeutic options \napproved for ulcerative colitis, but did not include \nrecent data related to small molecule drugs.9\u201313 \nAdditionally, subcutaneous formulations of infliximab \nand vedolizumab were approved by the European \nMedicines Agency in 2020 for the treatment of ulcerative \ncolitis and Crohn\u2019s disease. The aim of this systematic \nreview and network meta-analysis is to give an updated \ncomparison of the relative efficacy and safety of biologics \nand small molecule drugs (approved or in a late stage of \ndevelopment) in the treatment of patients with moderate-\nto-severe ulcerative colitis.\nMethods \nSearch strategy and selection criteria \nThis systematic review and network meta-analysis was \ndone by use of an a priori established protocol, and \nis reported according to the Preferred Reporting"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 8.0, "text": "vedolizumab was superior to adalimumab for mainte-\nnance of clinical remission and endoscopic improvement\n(Supplementary Table 2A; Supplementary Figure 4); no\nsigni\ufb01cant differences were observed between in\ufb02iximab\nand vedolizumab (clinical remission: OR, 0.72; 95% CI,\n0.35\u20131.49; endoscopic improvement: OR, 0.73; 95% CI,\n0.37\u20131.42). Vedolizumab was ranked highest (SUCRA,\nmaintenance\nof\nclinical\nremission\nand\nendoscopic\nimprovement, 0.93 and 0.94, respectively), followed by\nTable 4. Comparative Safety of Pharmacologic Agents During Maintenance Therapy in Patients With Moderate\u2013Severe Ulcerative Colitis Using Network Meta-Analysis\nRisk of serious adverse events\nRisk of infections\nUstekinumab 90 mg q8w\n1.14 (0.37\u20133.50)\n1.18 (0.50\u20132.79)\n0.43 (0.15\u20131.22)\n0.85 (0.37\u20131.92)\n1.32 (0.56\u20133.12)\n0.87 (0.42\u20131.79)\n0.63 (0.35\u20131.16)\nTofacitinib 5 mg b.d.\n1.03 (0.39\u20132.71)\n0.38 (0.12\u20131.17)\n0.74 (0.29\u20131.87)\n1.15 (0.44\u20133.02)\n0.76 (0.32\u20131.77)\n1.13 (0.66\u20131.93)\n1.78 (1.02\u20133.09)\nVedolizumab\n0.37 (0.15\u20130.88)"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 4.0, "text": "PURSUIT, Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment; q2w, every 2 weeks; q4w, every 4 weeks; q8w, every 8 weeks; TNF, tumor necrosis factor; VDZ, vedolizumab.\naMaintenance therapy with treat straight-through design.\nbMedian (range).\ncReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 0%; secondary loss of response or intolerance, 100%.\ndOnly including patients with initial response to induction therapy who were rerandomized to placebo or active intervention.\neReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 48%; secondary loss of response, 38%; intolerance, 14%.\nfReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 36%; secondary loss of response, 30%; intolerance, 18%.\ngReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 58%; secondary loss of response, 40%; intolerance, 2%."}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 5.0, "text": "Colitis, 2020. Comorbidity, not patient age, is associated with impaired safety\noutcomes in vedolizumab- and ustekinumab-treated patients with in\ufb02ammatory\nbowel disease-a prospective multicentre cohort study. Aliment. Pharmacol. Ther. 52\n(8), 1366\u20131376.\nAtreya, R., Siegmund, B., 2021. Location is important: differentiation between ileal and\ncolonic crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 18 (8), 544\u2013558.\nBek, S., Nielsen, J.V., Bojesen, A.B., Franke, A., Bank, S., Vogel, U., Andersen, V., 2016.\nSystematic review: genetic biomarkers associated with anti-tnf treatment response in\nin\ufb02ammatory bowel diseases. Aliment. Pharmacol. Ther. 44 (6), 554\u2013567.\nBen-Horin, S., Novack, L., Mao, R., Guo, J., Zhao, Y., Sergienko, R., Zhang, J.,\nKobayashi, T., Hibi, T., Chowers, Y., Peyrin-Biroulet, L., Colombel, J.F., Kaplan, G.G.,\nChen, M.H., 2021. Ef\ufb01cacy of biologic drugs in short-duration versus long-duration\nin\ufb02ammatory bowel disease: a systematic review and an individual-patient data"}]}, {"question": "28 year old woman who has severe extensive ulcerative colitis and has a history of lymphoma which was treated 4 years ago\n", "answer": "I don't know", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:\nWe searched publication databases through September 30, 2019, for randomized trials of\nadults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\ntofacitinib, or ustekinumab, as \ufb01rst-line or second-line agents, compared with placebo or\nanother active agent. Ef\ufb01cacy outcomes were induction and maintenance of remission and\nendoscopic improvement; safety outcomes were serious adverse events and infections. We\nperformed a \ufb01xed-effects network meta-analysis using the frequentist approach, and calculated\nodds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\nranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\nRecommendations, Assessment, Development and Evaluation).\nRESULTS:"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7.0, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2.0, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "patients with moderate\u2013severe ulcerative colitis with\nprior exposure to TNFa antagonists (Figure 2B). With an\nestimated placebo rate of achieving clinical remission of\n3% in included trials, we estimated that 3.2%, 5.6%,\n26.9%, and 26.3% of adalimumab-, vedolizumab-, tofaci-\ntinib-, and ustekinumab-treated patients, respectively,\nwould achieve induction of remission.\nInduction of endoscopic improvement. On direct meta-\nanalysis, tofacitinib and ustekinumab, but not vedolizumab\nor adalimumab, were superior to placebo for induction of\nendoscopic improvement, with minimal heterogeneity\nTable 3. Comparative Ef\ufb01cacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in\nPatients With Moderate\u2013Severe Ulcerative Colitis With Prior Exposure to Tumor Necrosis Factor-a Antagonists Using\nNetwork Meta-Analysis\nInduction of clinical remission\nInduction of endoscopic\nimprovement\nUstekinumab 6 mg/kg\n0.97 (0.11\u20138.72)\n5.99 (1.13\u201331.76)\n10.71 (2.01\u201357.20)"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 5.0, "text": "Burr et al. \n \n5 of 45 \nSTUDY HIGHLIGHTS \n \nWhat is already known about this subject \n\u2022 Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \nflares of disease activity, some of which may be moderate to severe. \n\u2022 These are usually treated with corticosteroids, which have potentially serious adverse \neffects, so biological therapies and small molecules have been developed and licensed \nfor this indication.  \n\u2022 Although previous network meta-analyses have compared their efficacy and safety, \nthis is a rapidly moving field, and there are already several newer drugs that have \nshown efficacy in phase III clinical trials that were not considered in these. \n \nWhat are the new findings \n\u2022 In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \nfirst in all patients, in patients previously exposed to anti-tumour necrosis factor \n(TNF)-\u03b1 therapies, and in patients na\u00efve to these drugs."}]}, {"question": "36 year old woman with moderate ulcerative colitis and multiple sclerosis\n", "answer": "I don't know", "sources": [{"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 7.0, "text": "multiple sclerosis and ulcerative colitis in the USA. Another \nmeta-analysis showed that sphingosine 1-phosphate \nmodulators are associated with an increased risk of herpes \nzoster infection and transient cardiovascular events.45\nOur study has several limitations besides the usual \nlimitations of network meta-analyses. First, data from \nsome clinical trials with newer small molecule drugs were \nextracted from conference abstracts, and the full data could \nnot be completely analysed. Notably, we could only analyse \noutcomes for the overall population as the main analysis, \nand not according to previous exposure to biologics. We \ndid do an exploratory analysis according to previous \nbiologic exposure, but data for upadacitinib could not be \nincluded. Second, no phase 3 RCTs with etrasimod or \nTD-1473 were found; results from phase 3 clinical trials \ntesting novel small molecule drugs (eg, etrasimod) in \npatients with moderate-to-severe ulcerative colitis are"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 5.0, "text": "Group, G.C.S., 2018. Ef\ufb01cacy of adalimumab in patients with crohn's disease and\nsymptomatic small bowel stricture: a multicentre, prospective, observational cohort\n(creole) study. Gut 67 (1), 53\u201360.\nChandrakumar, A., Georgy, M., Agarwal, P., Jong, G.W. t, El-Matary, W., 2019. Anti-\nsaccharomyces cerevisiae antibodies as a prognostic biomarker in children with\ncrohn disease. J. Pediatr. Gastroenterol. Nutr. 69 (1), 82\u201387.\nCheng, D., Cushing, K.C., Cai, T., Ananthakrishnan, A.N., 2021. Safety and ef\ufb01cacy of\ntumor necrosis factor antagonists in older patients with ulcerative colitis: patient-\nlevel pooled analysis of data from randomized trials. Clin. Gastroenterol. Hepatol. 19\n(5), 939\u2013946.\nChristensen, B., Micic, D., Gibson, P.R., Yarur, A., Bellaguarda, E., Corsello, P.,\nGaetano, J.N., Kinnucan, J., Rao, V.L., Reddy, S., Singh, S., Pekow, J., Rubin, D.T.,\n2018. Vedolizumab in patients with concurrent primary sclerosing cholangitis and"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "", "filename": "otad009.pdf", "page": 0.0, "text": "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\nReceived for publication: September 21, 2022. Editorial Decision: January 25, 2023\n \nDownloaded from https://academic.oup.com/crohnscolitis360/article/5/2/otad009/7066911 by National University of Singapore user on 23 May 2023"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "in induction trials, we estimated that 58.7%, 40.4%,\n42.7%, 51.9%, 46.5%, and 44.4% of in\ufb02iximab-, adali-\nmumab-, golimumab-, vedolizumab-, tofacitinib-, and\nustekinumab-treated patients, respectively, would ach-\nieve induction of endoscopic improvement.\nSecond-line\npharmacotherapy\nfor\nmoderate\u2013severe\nulcerative colitis. Overall, 7 RCTs including 1580 pa-\ntients with moderate\u2013severe ulcerative colitis with prior\nexposure to TNFa antagonists were identi\ufb01ed. These\nincluded subgroup analyses of trials of adalimumab,21\nvedolizumab,24,25\ntofacitinib,26\nand\nustekinumab.7\nThere were no trials of in\ufb02iximab or golimumab in\npatients with prior exposure to TNFa antagonists who\nmet inclusion criteria. In trials of adalimumab, only pa-\ntients with loss of response or intolerance to a prior\nTNFa antagonist were included. In contrast, in trials of\nvedolizumab, 48% to 58% of patients had inadequate\nresponse to a TNFa antagonist, and in trials of usteki-"}]}, {"question": "39 year-old male with moderate to severe extensive ulcerative colitis who had malignant melanoma which was treated 3 years ago\n", "answer": "I don't know", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:\nWe searched publication databases through September 30, 2019, for randomized trials of\nadults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\ntofacitinib, or ustekinumab, as \ufb01rst-line or second-line agents, compared with placebo or\nanother active agent. Ef\ufb01cacy outcomes were induction and maintenance of remission and\nendoscopic improvement; safety outcomes were serious adverse events and infections. We\nperformed a \ufb01xed-effects network meta-analysis using the frequentist approach, and calculated\nodds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\nranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\nRecommendations, Assessment, Development and Evaluation).\nRESULTS:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "patients with moderate\u2013severe ulcerative colitis with\nprior exposure to TNFa antagonists (Figure 2B). With an\nestimated placebo rate of achieving clinical remission of\n3% in included trials, we estimated that 3.2%, 5.6%,\n26.9%, and 26.3% of adalimumab-, vedolizumab-, tofaci-\ntinib-, and ustekinumab-treated patients, respectively,\nwould achieve induction of remission.\nInduction of endoscopic improvement. On direct meta-\nanalysis, tofacitinib and ustekinumab, but not vedolizumab\nor adalimumab, were superior to placebo for induction of\nendoscopic improvement, with minimal heterogeneity\nTable 3. Comparative Ef\ufb01cacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in\nPatients With Moderate\u2013Severe Ulcerative Colitis With Prior Exposure to Tumor Necrosis Factor-a Antagonists Using\nNetwork Meta-Analysis\nInduction of clinical remission\nInduction of endoscopic\nimprovement\nUstekinumab 6 mg/kg\n0.97 (0.11\u20138.72)\n5.99 (1.13\u201331.76)\n10.71 (2.01\u201357.20)"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2.0, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "SYSTEMATIC REVIEWS AND META-ANALYSES\nSiddharth Singh, Section Editor\nFirst- and Second-Line Pharmacotherapies for Patients With\nModerate to Severely Active Ulcerative Colitis: An Updated\nNetwork Meta-Analysis\nSiddharth Singh,*,\u2021 Mohammad Hassan Murad,\u00a7 Mathurin Fumery,j\nParambir S. Dulai,* and William J. Sandborn*\n*Division of Gastroenterology, \u2021Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n\u00a7Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Universit\u00e9 de Picardie Jules Verne, Amiens, France\nBACKGROUND & AIMS:\nWe compared the ef\ufb01cacy and safety of different \ufb01rst-line (biologic-na\u00efve) and second-line\n(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "What You Need to Know\nBackground\nA systematic review and network meta-analysis is\nneeded to compare ef\ufb01cacy and safety of \ufb01rst-line\n(biologic-na\u00efve) and second-line (prior exposure to\ntumor necrosis factor [TNF] antagonists) agents for\ntreatment of moderate to severely active ulcerative\ncolitis.\nFindings\nIn\ufb02iximab was ranked highest in biologic-na\u00efve pa-\ntients, and ustekinumab and tofacitinib were ranked\nhighest in patients with prior exposure to TNF an-\ntagonists, for induction of remission and endoscopic\nimprovement. More trials of direct comparisons are\nneeded to inform clinical decision-making with\ngreater con\ufb01dence.\nImplications for patient care\nPatients with moderate to severely active ulcerative\ncolitis should receive in\ufb02iximab or vedolizumab as\n\ufb01rst-line therapy, or ustekinumab or tofacitinib if\nthey have prior exposure to TNF antagonists.\n2180 Singh et al\nClinical Gastroenterology and Hepatology Vol. 18, No. 10"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}]}, {"question": "52 year-old woman with moderate to severe distal ulcerative colitis that had a successful induction with vedolizumab. What would be the maintenance therapy?\n", "answer": "The maintenance therapy for this patient would likely continue to be Vedolizumab, given the successful induction. This is because Vedolizumab has been shown to be effective in maintaining remission in patients with moderate to severe ulcerative colitis who have responded to induction therapy with the same drug.", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 5.0, "text": "Patients across all trials and treatment arms were com-\nparable in terms of baseline prognostic variables, inclu-\nsion/exclusion\ncriteria,\nand\nco-interventions.\nAll\noutcomes were assessed uniformly based on the stan-\ndard de\ufb01nition of the Mayo Clinic score, between weeks\n6 and 10 for induction therapy (in\ufb02iximab, adalimumab,\ntofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\nvedolizumab, 6 weeks, 10 weeks, and 14 weeks in\nVARSITY),6 and weeks 30, 54, or 60 for maintenance\ntherapy;\nendoscopy\nwas\nread\nby\nblinded\nlocal\nTable 2. Comparative Ef\ufb01cacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in Biologic-Naive Patients With Moderate\u2013Severe\nUlcerative Colitis Using Network Meta-Analysis\nInduction of clinical remission\nInduction of endoscopic improvement\nUstekinumab 6 mg/kg\n0.96 (0.38\u20132.45)\n0.80 (0.35\u20131.83)\n0.73 (0.31\u20131.74)\n1.05 (0.48\u20132.32)\n0.50 (0.22\u20131.12)\n2.04 (1.03\u20134.05)\n0.92 (0.45\u20131.89)\nTofacitinib 10 mg b.d.\n0.84 (0.39\u20131.82)"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 7.0, "text": "compared. Results of our post-hoc, direct, pairwise meta-\nanalysis for histological remission are shown in the \nappendix (p 28).\nDiscussion \nWe reviewed available efficacy and safety data from RCTs \nof biologics and small molecule drugs (approved or in a \nlate stage of development) for induction and maintenance \ntreatment of patients with moderate-to-severe ulcerative \ncolitis. All small molecule drugs and approved biologics, \nexcept filgotinib 100 mg, were significantly better than \nplacebo in terms of inducing clinical remission and \nendoscopic improvement. A novel finding of this study \nwas that upadacitinib ranked highest for the induction of \nclinical remission and endoscopic improvement, and \nwas notably superior for these outcomes to all other \ninterventions in our network meta-analysis. Infliximab \nranked second for both outcomes. Regarding safety, \nvedolizumab was still ranked as the safest drug in \nterms of adverse events and serious adverse events, as \npreviously \nobserved"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8.0, "text": "(ie, tofacitinib, ozanimod, filgotinib, and upadacitinib). \nFifth, we analysed steroid-free remission\u2014a more robust \nand \nclinically \nmeaningful \noutcome \nthan \nclinical \nremission\u2014in maintenance trials only, as corticosteroid \ntapering was not allowed in induction trials. In addition, \nnot all clinical trials reported on steroid-free remission, \nparticularly the older trials. Finally, some preliminary \nreports, such as the trial of maintenance with subcutaneous \nvedolizumab, did not report relevant data for endoscopic \nimprovement. \nAs with any indirect comparison, the results presented \nin this study should be interpreted with caution but could \nhelp clinicians to navigate the current scenario in which \nthe number of therapeutic options for moderate-to-\nsevere ulcerative colitis is steadily increasing. These \nfindings should be interpreted as hypothesis-generating, \nuntil direct comparisons by means of head-to-head trials \nbecome available to fully elucidate the positioning of"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 11.0, "text": "tive colitis. Aliment Pharmacol Ther 2018;47:454\u2013465.\n5.\nSingh S, Fumery M, Sandborn WJ, et al. Systematic review with\nnetwork meta-analysis: \ufb01rst- and second-line pharmacotherapy\nfor moderate-severe ulcerative colitis. Aliment Pharmacol Ther\n2018;47:162\u2013175.\n6.\nSands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. Vedolizumab\nversus adalimumab for moderate-to-severe ulcerative colitis.\nN Engl J Med 2019;381:1215\u20131226.\n7.\nSands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as\ninduction and maintenance therapy for ulcerative colitis. N Engl\nJ Med 2019;381:1201\u20131214.\n8.\nPuhan MA, Schunemann HJ, Murad MH, et al. A GRADE Working\nGroup approach for rating the quality of treatment effect esti-\nmates from network meta-analysis. BMJ 2014;349:g5630.\n9.\nHutton B, Salanti G, Caldwell DM, et al. The PRISMA extension\nstatement for reporting of systematic reviews incorporating\nnetwork meta-analyses of health care interventions: checklist\nand explanations. Ann Intern Med 2015;162:777\u2013784.\n10."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "vs adalimumab: OR, 11.05; 95% CI, 1.79\u201368.41; moderate CE). Vedolizumab had the lowest risk\nof infections (SUCRA, 0.81), followed by ustekinumab (SUCRA, 0.63) in maintenance trials.\nCONCLUSIONS:\nIn a systematic review and network meta-analysis, we found in\ufb02iximab to be ranked highest in\nbiologic-na\u00efve patients, and ustekinumab and tofacitinib were ranked highest in patients with\nprior exposure to TNF antagonists, for induction of remission and endoscopic improvement in\npatients with moderate to severe ulcerative colitis. More trials of direct comparisons are\nneeded to inform clinical decision making with greater con\ufb01dence.\nKeywords: GRADE; Pharmacotherapy; In\ufb02ammatory Bowel Disease; UC; Comparative Ef\ufb01cacy.\nU\nlcerative colitis affects 1 in 200 to 1 in 400 people\nin Western nations, and its global incidence and\nprevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 10.0, "text": "subsequent trials of vedolizumab, tofacitinib, and uste-\nkinumab, a signi\ufb01cant proportion of patients may have\nbeen exposed to 2 or more biologic agents before clinical\ntrial intervention, and inherently may be dif\ufb01cult to treat.\nHowever,\ntrials\nof\nustekinumab\nwere\nconducted\nfollowing approval of vedolizumab, and a subset of pa-\ntients in these trials failed multiple TNFa antagonists and\nvedolizumab, conceivably making it a more refractory\npatient population. Despite this, we observed the supe-\nriority of ustekinumab over vedolizumab, suggesting the\neffect likely is real and not confounded by treatment\nrefractoriness.\nIn this study, by updating analyses with the inclusion\nof ustekinumab, accounting for dose change for tofaciti-\nnib, including a head-to-head trial of biologics in\nmoderate\u2013severe\nulcerative\ncolitis,\nappropriately\ncomparing trials of maintenance therapy with different\ndesigns, adding the GRADE framework and assessment\nof absolute effect size, and performing a thorough"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 6.0, "text": "investigators for all trials, except trials of tofacitinib and\nustekinumab, which were read by blinded central\nreaders.7,26 Overall, the studies were deemed to be at\nlow risk of bias, and all included studies were industry-\nsponsored.\nInduction Therapy\nFirst-line\npharmacotherapy\nfor\nmoderate\u2013severe\nulcerative colitis. Overall, 15 RCTs including 3747 bio-\nlogic-na\u00efve patients with moderate\u2013severe ulcerative\ncolitis, treated with in\ufb02iximab (4 trials, 667 patients),\nadalimumab (4 trials, 1046 patients), golimumab (2 tri-\nals, 586 patients), vedolizumab (3 trials, 630 patients),\ntofacitinib (2 trials, 520 patients), and ustekinumab (1\ntrial, 298 patients) were included; 1 trial compared\nadalimumab vs vedolizumab.\nInduction\nof\nclinical\nremission. On\ndirect\nmeta-\nanalysis, all agents were superior to placebo for induc-\ntion of clinical remission, and effect size was strongest\nfor in\ufb02iximab (OR, 4.07; 95% CI, 2.68\u20136.16) and vedoli-\nzumab (OR, 3.10; 95% CI, 1.53\u20136.26), with minimal to"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "in induction trials, we estimated that 58.7%, 40.4%,\n42.7%, 51.9%, 46.5%, and 44.4% of in\ufb02iximab-, adali-\nmumab-, golimumab-, vedolizumab-, tofacitinib-, and\nustekinumab-treated patients, respectively, would ach-\nieve induction of endoscopic improvement.\nSecond-line\npharmacotherapy\nfor\nmoderate\u2013severe\nulcerative colitis. Overall, 7 RCTs including 1580 pa-\ntients with moderate\u2013severe ulcerative colitis with prior\nexposure to TNFa antagonists were identi\ufb01ed. These\nincluded subgroup analyses of trials of adalimumab,21\nvedolizumab,24,25\ntofacitinib,26\nand\nustekinumab.7\nThere were no trials of in\ufb02iximab or golimumab in\npatients with prior exposure to TNFa antagonists who\nmet inclusion criteria. In trials of adalimumab, only pa-\ntients with loss of response or intolerance to a prior\nTNFa antagonist were included. In contrast, in trials of\nvedolizumab, 48% to 58% of patients had inadequate\nresponse to a TNFa antagonist, and in trials of usteki-"}]}, {"question": "24 year-old man with moderate to severe extensive ulcerative colitis previously in clinical remission with infliximab develops loss of response due to antibody formation.\n", "answer": "[\n{\n\"drug_name\": \"Vedolizumab\",\n\"advantages\": \"Vedolizumab is an anti-integrin antibody that has been shown to be effective in inducing clinical remission in patients with moderate-to-severe ulcerative colitis. It has a different mechanism of action compared to infliximab, so it may be effective in patients who have developed antibodies to infliximab. It is also considered to be one of the safest drugs in terms of adverse events and serious adverse events.\",\n\"disadvantages\": \"The response to vedolizumab may take longer to manifest compared to anti-TNF agents like infliximab. Some patients may not respond to vedolizumab treatment.\"\n},\n{\n\"drug_name\": \"Ustekinumab\",\n\"advantages\": \"Ustekinumab is an anti-interleukin-12/23 antibody that has been shown to be effective in inducing clinical remission in patients with moderate-to-severe ulcerative colitis. It has a different mechanism of action compared to infliximab, so it may be effective in patients who have developed antibodies to infliximab.\",\n\"disadvantages\": \"Ustekinumab may not be as effective as some other biologics in inducing clinical remission. It also requires an initial intravenous infusion, followed by subcutaneous injections, which some patients may find inconvenient.\"\n}\n]", "sources": [{"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 4.0, "text": "of bias for most of the included studies (appendix p 5). \nConfidence in the estimates derived from our meta-\nanalysis is shown in the appendix (pp 6\u20138).\nA network map of induction trials assessing clinical \nremission in patients with moderate-to-severe ulcerative \ncolitis is shown in figure 2. When evaluating the \ninduction of clinical remission, all interventions, except \nfor filgotinib 100 mg (OR 1\u00b755, 95% CI 0\u00b798\u20132\u00b746), were \nsignificantly superior to placebo in the direct, pairwise \nmeta-analysis (appendix p 9); overall heterogeneity was \nsubstantial (I\u00b2=81%). The results from our network meta-\nanalysis are shown in figure 3. When comparing active \ntreatments, adalimumab (OR 0\u00b754, 95% CI 0\u00b737\u20130\u00b779; \nmoderate confidence), etrolizumab (0\u00b751, 0\u00b736\u20130\u00b772; \nhigh confidence), filgotinib 100 mg (0\u00b741, 0\u00b723\u20130\u00b771; \nmoderate confidence), and filgotinib 200 mg (0\u00b756, \n0\u00b732\u20130\u00b797; moderate confidence) were significantly \ninferior to infliximab in inducing clinical remission."}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 7.0, "text": "compared. Results of our post-hoc, direct, pairwise meta-\nanalysis for histological remission are shown in the \nappendix (p 28).\nDiscussion \nWe reviewed available efficacy and safety data from RCTs \nof biologics and small molecule drugs (approved or in a \nlate stage of development) for induction and maintenance \ntreatment of patients with moderate-to-severe ulcerative \ncolitis. All small molecule drugs and approved biologics, \nexcept filgotinib 100 mg, were significantly better than \nplacebo in terms of inducing clinical remission and \nendoscopic improvement. A novel finding of this study \nwas that upadacitinib ranked highest for the induction of \nclinical remission and endoscopic improvement, and \nwas notably superior for these outcomes to all other \ninterventions in our network meta-analysis. Infliximab \nranked second for both outcomes. Regarding safety, \nvedolizumab was still ranked as the safest drug in \nterms of adverse events and serious adverse events, as \npreviously \nobserved"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 6.0, "text": "were signi\ufb01cantly different (Table 2). Overall, in\ufb02iximab\n(SUCRA, 0.95) was ranked highest for inducing clinical\nremission\nin\nbiologic-na\u00efve\npatients\nwith\nmoderate\u2013severe UC (Figure 2A). With an estimated\nplacebo rate of achieving remission of 10% in included\ntrials, we anticipate that 31.1%, 17.7%, 23.7%, 22.0%,\nFigure 2. (A) Relative ef\ufb01-\ncacy\nof\ndifferent\nin-\nterventions for induction of\nclinical\nremission\nand\nendoscopic\nimprovement\nin biologic-na\u00efve patients\nwith moderate to severely\nactive ulcerative colitis. (B)\nRelative\nef\ufb01cacy\nof\ndifferent interventions for\ninduction of clinical remis-\nsion\nand\nendoscopic\nimprovement\nin\npatients\nwith moderate to severely\nactive\nulcerative\ncolitis\nwith prior exposure to tu-\nmor necrosis factor (TNF)\u237a\nantagonists. SUCRA, sur-\nface under the cumulative\nranking.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2185"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 9.0, "text": "(infliximab, adalimumab, or golimumab), anti-integrin antibodies (vedolizumab or \netrolizumab), or anti-interleukin-12/23 antibodies (ustekinumab)) or small molecules (janus \nkinase inhibitors (tofacitinib, filgotinib, or upadacitinib) or sphingosine-1-phosphate receptor \nmodulators (ozanimod)) at the doses taken through into testing in phase III clinical trials. \nStudies had to recruit ambulatory adults (\u226518 years) with moderate to severely active UC \n(Supplementary Table 1), and compared biological therapies or small molecules with \nplacebo, or with each other. We required a minimum follow-up duration of 6 weeks.  \nTwo investigators (NEB and ACF) conducted independent literature searches. We \nidentified studies on UC with the terms: inflammatory bowel disease, colitis, or ulcerative \ncolitis (both as medical subject headings and free text terms). We combined these using the \nset operator AND with studies identified with the following terms: infliximab, remicade,"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "meta-analysis. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2022.07.032 \n(2022).\n5. \nBurr, N. E. et al. Efficacy of biological therapies and small molecules in moderate to  \nsevere ulcerative colitis: systematic review and network meta-analysis. Gut 71, 1976\u20131987 \n(2022).\n6. Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid \narthritis. N. Engl. J. Med. 386, 316\u2013326 (2022).\n7. \nBiasci, D. et al. A blood-based prognostic biomarker in IBD. Gut 68, 1386\u20131395 (2019).\n8. Verstockt, B., Parkes, M. & Lee, J. C. How do we predict a patient\u2019s disease course and \nwhether they will respond to specific treatments? Gastroenterology 162, 1383\u20131395 \n(2022).\n9. \nSazonovs, A. et al. HLA-DQA1*05 carriage associated with development of anti-\ndrug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease. \nGastroenterology 158, 189\u2013199 (2020).\n10. Nguyen, N. H., Singh, S. & Sandborn, W. J. Positioning therapies in the management"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 6.0, "text": "investigators for all trials, except trials of tofacitinib and\nustekinumab, which were read by blinded central\nreaders.7,26 Overall, the studies were deemed to be at\nlow risk of bias, and all included studies were industry-\nsponsored.\nInduction Therapy\nFirst-line\npharmacotherapy\nfor\nmoderate\u2013severe\nulcerative colitis. Overall, 15 RCTs including 3747 bio-\nlogic-na\u00efve patients with moderate\u2013severe ulcerative\ncolitis, treated with in\ufb02iximab (4 trials, 667 patients),\nadalimumab (4 trials, 1046 patients), golimumab (2 tri-\nals, 586 patients), vedolizumab (3 trials, 630 patients),\ntofacitinib (2 trials, 520 patients), and ustekinumab (1\ntrial, 298 patients) were included; 1 trial compared\nadalimumab vs vedolizumab.\nInduction\nof\nclinical\nremission. On\ndirect\nmeta-\nanalysis, all agents were superior to placebo for induc-\ntion of clinical remission, and effect size was strongest\nfor in\ufb02iximab (OR, 4.07; 95% CI, 2.68\u20136.16) and vedoli-\nzumab (OR, 3.10; 95% CI, 1.53\u20136.26), with minimal to"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 9.0, "text": "induction of remission than prior estimates, and the\nsigni\ufb01cantly superior ef\ufb01cacy of ustekinumab and tofa-\ncitinib over vedolizumab as second-line agents in pa-\ntients with prior exposure to TNFa antagonists. With\nlimited head-to-head trials, this information can inform\nclinical practice and guidelines directly and facilitate\nshared decision making for management of patients with\nmoderate\u2013severe ulcerative colitis.\nOur\nresults\ncon\ufb01rm\nseveral\nprior\nobservational\ncomparative effectiveness studies, individual patient-\nlevel analyses of clinical trials, and indirect treatment\ncomparison network meta-analyses suggesting higher\nef\ufb01cacy and effectiveness of in\ufb02iximab over adalimumab\nand golimumab.4,5,29,30 This may be related to differ-\nences\nin\npharmacokinetics\nand\nbioavailability\nwith\ndifferent dosing schema (weight-based vs \ufb01xed dose)\nand route of administration. The recent Study to Evaluate\nthe Safety and Ef\ufb01cacy of Two Drug Regimens in Subjects"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 11.0, "text": "353:2462\u20132476.\n18.\nJiang XL, Cui HF, Gao J, et al. Low-dose in\ufb02iximab for induction\nand maintenance treatment in Chinese patients with moderate\nto severe active ulcerative colitis. J Clin Gastroenterol 2015;\n49:582\u2013588.\n19.\nXian-Janssen. A study to evaluate the effectiveness and safety\nof in\ufb02iximab in Chinese patients with active ulcerative colitis.\n2015.\nAvailable\nfrom:\nhttps://clinicaltrials.gov/ct2/show/\nNCT01551290. Accessed June 5, 2017.\n20.\nReinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for\ninduction of clinical remission in moderately to severely active\nulcerative colitis: results of a randomised controlled trial. Gut\n2011;60:780\u2013787.\n2190 Singh et al\nClinical Gastroenterology and Hepatology Vol. 18, No. 10"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "randomised responder trials are also presented. This study is registered with PROSPERO, CRD42021225329.\nFindings Our search yielded 5904 results, from which 29 studies (four being head-to-head RCTs) fulfilled our inclusion \ncriteria and were included. Of these, 23 studies assessed induction therapy with either a biologic or small molecule \ndrug, comprising 10 061 patients with ulcerative colitis. A risk of bias assessment showed a low risk of bias for most \nof the included studies. Upadacitinib was significantly superior to all other interventions for the induction of clinical \nremission (infliximab [OR 2\u00b770, 95% CI 1\u00b718\u20136\u00b720], adalimumab [4\u00b764, 2\u00b747\u20138\u00b771], golimumab [3\u00b700, 1\u00b732\u20136\u00b782], \nvedolizumab [3\u00b756, 1\u00b784\u20136\u00b791], ustekinumab [2\u00b792, 1\u00b731\u20136\u00b751], etrolizumab [4\u00b791, 2\u00b759\u20139\u00b731], tofacitinib [2\u00b784, \n1\u00b728\u20136\u00b731], filgotinib 100 mg [6\u00b715, 2\u00b798\u201312\u00b772], filgotinib 200 mg [4\u00b749, 2\u00b718\u20139\u00b724], and ozanimod (2\u00b770,"}]}, {"question": "44 year-old woman with moderate to severe extensive ulcerative colitis and rheumatoid arthritis.\n", "answer": "Based on the patient's profile, the top two choices of biological drugs would be Infliximab and Vedolizumab. \n\nInfliximab is often favored as a first-line agent for moderate to severe ulcerative colitis. It has been shown to be effective in inducing and maintaining remission in ulcerative colitis. Additionally, it is also used in the treatment of rheumatoid arthritis, which the patient also has.\n\nVedolizumab is another first-line agent for moderate to severe ulcerative colitis. It is a gut-selective immunosuppressant, meaning it specifically targets inflammation in the gut, potentially leading to fewer systemic side effects.\n\nHere are the pros and cons of each:\n\nInfliximab:\n- Advantages: Effective in inducing and maintaining remission in ulcerative colitis, can also be used to treat rheumatoid arthritis, has a long track record and is generally well-tolerated.\n- Disadvantages: Risk of developing anti-drug antibodies which can decrease its effectiveness, potential for systemic side effects as it is not gut-selective, risk of serious infections and potential increased risk of certain cancers.\n\nVedolizumab:\n- Advantages: Effective in inducing and maintaining remission in ulcerative colitis, gut-selective which may lead to fewer systemic side effects.\n- Disadvantages: May not be as effective in treating rheumatoid arthritis, slower onset of action compared to other biologics, risk of serious infections.\n\nOutput:\n[\n  {\n    \"drug_name\": \"Infliximab\",\n    \"advantages\": \"Effective in inducing and maintaining remission in ulcerative colitis, can also be used to treat rheumatoid arthritis, has a long track record and is generally well-tolerated.\",\n    \"disadvantages\": \"Risk of developing anti-drug antibodies which can decrease its effectiveness, potential for systemic side effects as it is not gut-selective, risk of serious infections and potential increased risk of certain cancers.\"\n  },\n  {\n    \"drug_name\": \"Vedolizumab\",\n    \"advantages\": \"Effective in inducing and maintaining remission in ulcerative colitis, gut-selective which may lead to fewer systemic side effects.\",\n    \"disadvantages\": \"May not be as effective in treating rheumatoid arthritis, slower onset of action compared to other biologics, risk of serious infections.\"\n  }\n]", "sources": [{"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "meta-analysis. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2022.07.032 \n(2022).\n5. \nBurr, N. E. et al. Efficacy of biological therapies and small molecules in moderate to  \nsevere ulcerative colitis: systematic review and network meta-analysis. Gut 71, 1976\u20131987 \n(2022).\n6. Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid \narthritis. N. Engl. J. Med. 386, 316\u2013326 (2022).\n7. \nBiasci, D. et al. A blood-based prognostic biomarker in IBD. Gut 68, 1386\u20131395 (2019).\n8. Verstockt, B., Parkes, M. & Lee, J. C. How do we predict a patient\u2019s disease course and \nwhether they will respond to specific treatments? Gastroenterology 162, 1383\u20131395 \n(2022).\n9. \nSazonovs, A. et al. HLA-DQA1*05 carriage associated with development of anti-\ndrug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease. \nGastroenterology 158, 189\u2013199 (2020).\n10. Nguyen, N. H., Singh, S. & Sandborn, W. J. Positioning therapies in the management"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 11.0, "text": "should be discussed adequately with patients.\nIntegrating \ufb01ndings from this meta-analysis and other\nstudies, current evidence favors in\ufb02iximab or vedolizu-\nmab\nas\nthe\npreferred\n\ufb01rst-line\nagents\nfor\nmoderate\u2013severe ulcerative colitis. In patients who fail\nin\ufb02iximab, ustekinumab and tofacitinib likely would be\nmost ef\ufb01cacious, and ustekinumab\u2019s superior safety\npro\ufb01le may be attractive in light of recent concerns\naround\nvenous\nthromboembolism\nwith\ntofacitinib.\nHowever, besides quality of evidence, several other fac-\ntors including a balance of risk\u2013bene\ufb01t pro\ufb01le, speci\ufb01c\npatient attributes (age, comorbid conditions including\nrheumatic or dermatologic diseases, and so forth), clin-\nical judgment and experience of the treating physicians,\nvalues\nand\npreferences\nof\npatients\n(dosing\nroute,\nregimen, acceptability of risk\u2013bene\ufb01t trade-offs, and so\nforth), as well as the costs/resources available, are\nimportant to facilitate shared decision making, in devel-"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 1.0, "text": "OR \u201cinfliximab\u201d OR \u201cadalimumab\u201d OR (\u201cgolimumab\u201d \nOR \u201cCNTO-148\u201d) OR \u201canti-integrin\u201d OR (\u201cvedolizumab\u201d \nOR \u201cMLN-0002\u201d) OR (\u201cetrolizumab\u201d OR \u201crhuMAb \nBeta7\u201d) OR (\u201custekinumab\u201d OR \u201cCNTO-1275\u201d) OR \u201cJAK \ninhibitor\u201d OR (\u201ctofacitinib\u201d OR \u201cCP-690550\u201d) OR \n(\u201cfilgotinib\u201d OR \u201cGLPG0634\u201d) OR (\u201cupadacitinib\u201d OR \n\u201cABT-494\u201d) \nOR \n\u201csphingosine-1-phosphate \nreceptor \nmodulator\u201d OR (\u201cozanimod\u201d OR \u201cRPC1063\u201d) OR \n\u201cetrasimod\u201d OR \u201cTD-1473\u201d] AND [\u201culcerative colitis\u201d \nOR \u201cinflammatory bowel disease\u201d] AND [\u201cefficacy\u201d OR \nResearch in context\nEvidence before this study\nThe therapeutic armamentarium for moderate-to-severe \nulcerative colitis has expanded considerably in recent years. \nDrug development has shifted over the last decade to small \nmolecule drugs in an effort to overcome the intrinsic limitations \nof treatment with biologics. In this context of ever-expanding \ntreatment options, frequent updates of indirect comparisons \nare warranted. We searched MEDLINE, Embase, and the"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7.0, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A Users Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 7.0, "text": "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n\nRisk stratification: Mild\nClinical features: NA\nTreatment options: 5-ASA (oral and/or topical)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: VDZ or UST\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Thiopurine\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Psoriasis or psoriatic arthritis\nTreatment options: UST\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Other arthritis\nTreatment options: TNFi\n\n"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 5.0, "text": "with in\ufb02ammatory bowel disease: a systematic review and network meta-analysis.\nClin. Gastroenterol. Hepatol. 14 (10), 1385\u20131397.\nBonovas, S., Lytras, T., Nikolopoulos, G., Peyrin-Biroulet, L., Danese, S., 2018. Systematic\nreview with network meta-analysis: comparative assessment of tofacitinib and\nbiological therapies for moderate-to-severe ulcerative colitis. Aliment. Pharmacol.\nTher. 47 (4), 454\u2013465.\nBouhnik, Y., Carbonnel, F., Laharie, D., Stefanescu, C., Hebuterne, X., Abitbol, V.,\nNachury, M., Brixi, H., Bourreille, A., Picon, L., Bourrier, A., Allez, M., Peyrin-\nBiroulet, L., Moreau, J., Savoye, G., Fumery, M., Nancey, S., Roblin, X., Altwegg, R.,\nBouguen, G., Bommelaer, G., Danese, S., Louis, E., Zappa, M., Mary, J.Y.,\nGroup, G.C.S., 2018. Ef\ufb01cacy of adalimumab in patients with crohn's disease and\nsymptomatic small bowel stricture: a multicentre, prospective, observational cohort\n(creole) study. Gut 67 (1), 53\u201360."}]}, {"question": "55 year-old man with moderate to severe extensive ulcerative colitis who avlues convenience and limited time spent in hospital\n", "answer": "I don't know", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "(P A Olivera); Gastroenterology \nand Endoscopy, IRCCS Ospedale \nSan Raffaele and University \nVita-Salute San Raffaele, \nMilano, Italy \n(Prof S Danese MD); INSERM \nNGERE and Department of \nHepatogastroenterology, \nNancy University Hospital, \nLorraine University, \nVandoeuvre-l\u00e9s-Nancy, France \n(Prof L Peyrin-Biroulet MD) \nCorrespondence to: \nProf Laurent Peyrin-Biroulet, \nINSERM NGERE and Department \nof Hepatogastroenterology, \nNancy University Hospital, \nLorraine University, Vandoeuvre-\nl\u00e8s-Nancy F-54511, France \npeyrinbiroulet@gmail.com\nEfficacy and safety of biologics and small molecule drugs for \npatients with moderate-to-severe ulcerative colitis: \na systematic review and network meta-analysis \nJuan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\nSummary\nBackground There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 1.0, "text": "Burr et al. \n \n1 of 45 \nAccepted 2nd December 2021 \nTITLE PAGE \n \nTitle: Efficacy of Biological Therapies and Small Molecules in Moderate to Severe \nUlcerative Colitis: Systematic Review and Network Meta-analysis. \n \nShort title: Network Meta-analysis of Biological Therapies and Small Molecules for UC. \n \nAuthors: Nicholas E. Burr MD1,2, David J Gracie PhD1,2, Christopher J. Black PhD1,2*, \nAlexander C. Ford MD1,2*. \n*Joint last author \n \n1Leeds Gastroenterology Institute, St. James\u2019s University Hospital, Leeds, UK. \n2Leeds Institute of Medical Research at St. James\u2019s, University of Leeds, Leeds, UK. \n \nAbbreviations: \nCI \n \nconfidence interval \nRCT \n \nrandomised controlled trial \nRR \n \nrelative risk \nTNF \n \ntumour necrosis factor \nUC \n \nulcerative colitis \n \nCorrespondence: \nProfessor Alex Ford \nLeeds Gastroenterology Institute \nRoom 125 \n4th Floor"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "SYSTEMATIC REVIEWS AND META-ANALYSES\nSiddharth Singh, Section Editor\nFirst- and Second-Line Pharmacotherapies for Patients With\nModerate to Severely Active Ulcerative Colitis: An Updated\nNetwork Meta-Analysis\nSiddharth Singh,*,\u2021 Mohammad Hassan Murad,\u00a7 Mathurin Fumery,j\nParambir S. Dulai,* and William J. Sandborn*\n*Division of Gastroenterology, \u2021Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n\u00a7Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Universit\u00e9 de Picardie Jules Verne, Amiens, France\nBACKGROUND & AIMS:\nWe compared the ef\ufb01cacy and safety of different \ufb01rst-line (biologic-na\u00efve) and second-line\n(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 10.0, "text": "ulcerative\ncolitis,\nappropriately\ncomparing trials of maintenance therapy with different\ndesigns, adding the GRADE framework and assessment\nof absolute effect size, and performing a thorough\nquantitative and qualitative assessment of the safety of\ndifferent therapies, we have been able to contextualize\nour con\ufb01dence in the summary estimates for different\ncomparisons, and more thoroughly inform positioning of\ndifferent\nagents\nused\nin\nthe\ntreatment\nof\nmoderate\u2013severe ulcerative colitis. We acknowledge that\nthere is a paucity of head-to-head trials to truly inform\ncomparative ef\ufb01cacy and safety. However, it is important\nto note that across trials of induction therapy, key\ninclusion/exclusion criteria, outcome de\ufb01nitions, and\npatient and clinical characteristics, co-interventions were\ncomparable across trials, which facilitated this network\nmeta-analysis.\nBesides inherent limitations of individual trials, there\nwere limitations to our analyses. A thorough comparative"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "and corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis, \nnamely vedolizumab and, more recently, usteki numab. \nHowever, \ntreatment \nwith \nbiologics \nhas \nseveral \nlimit ations, including limited efficacy, primary non-\nresponse, secondary loss of response, immunogenicity,"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}]}, {"question": "60 year-old woman with severe ulcerative colitis that has loss response to anti-TNF, vedolizumab and ustekinumab\n", "answer": "Based on the patient's profile, the patient has severe ulcerative colitis and has failed prior treatments with anti-TNF agents, vedolizumab, and ustekinumab. Considering the patient's age and prior treatment failures, the top two choices of biological drugs could be Infliximab and Tofacitinib.\n\n[{\n\"drug_name\": \"Infliximab\",\n\"advantages\": \"Infliximab has been found to be highly effective in biologic-na\u00efve patients for induction of remission and endoscopic improvement in patients with moderate to severe ulcerative colitis. It has a higher efficacy and effectiveness over other drugs like adalimumab and golimumab.\",\n\"disadvantages\": \"Infliximab has a risk of serious infections. It may also not be as effective in patients who have had prior exposure to TNF antagonists.\"\n},\n{\n\"drug_name\": \"Tofacitinib\",\n\"advantages\": \"Tofacitinib has been found to be highly effective in patients with prior exposure to TNF antagonists for induction of remission and endoscopic improvement. It is also a good choice for patients who have failed other treatments.\",\n\"disadvantages\": \"Tofacitinib has been associated with a risk of venous thromboembolism. Its safety profile may not be as good as other drugs like ustekinumab.\"\n}]", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:\nWe searched publication databases through September 30, 2019, for randomized trials of\nadults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\ntofacitinib, or ustekinumab, as \ufb01rst-line or second-line agents, compared with placebo or\nanother active agent. Ef\ufb01cacy outcomes were induction and maintenance of remission and\nendoscopic improvement; safety outcomes were serious adverse events and infections. We\nperformed a \ufb01xed-effects network meta-analysis using the frequentist approach, and calculated\nodds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\nranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\nRecommendations, Assessment, Development and Evaluation).\nRESULTS:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "in induction trials, we estimated that 58.7%, 40.4%,\n42.7%, 51.9%, 46.5%, and 44.4% of in\ufb02iximab-, adali-\nmumab-, golimumab-, vedolizumab-, tofacitinib-, and\nustekinumab-treated patients, respectively, would ach-\nieve induction of endoscopic improvement.\nSecond-line\npharmacotherapy\nfor\nmoderate\u2013severe\nulcerative colitis. Overall, 7 RCTs including 1580 pa-\ntients with moderate\u2013severe ulcerative colitis with prior\nexposure to TNFa antagonists were identi\ufb01ed. These\nincluded subgroup analyses of trials of adalimumab,21\nvedolizumab,24,25\ntofacitinib,26\nand\nustekinumab.7\nThere were no trials of in\ufb02iximab or golimumab in\npatients with prior exposure to TNFa antagonists who\nmet inclusion criteria. In trials of adalimumab, only pa-\ntients with loss of response or intolerance to a prior\nTNFa antagonist were included. In contrast, in trials of\nvedolizumab, 48% to 58% of patients had inadequate\nresponse to a TNFa antagonist, and in trials of usteki-"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 9.0, "text": "induction of remission than prior estimates, and the\nsigni\ufb01cantly superior ef\ufb01cacy of ustekinumab and tofa-\ncitinib over vedolizumab as second-line agents in pa-\ntients with prior exposure to TNFa antagonists. With\nlimited head-to-head trials, this information can inform\nclinical practice and guidelines directly and facilitate\nshared decision making for management of patients with\nmoderate\u2013severe ulcerative colitis.\nOur\nresults\ncon\ufb01rm\nseveral\nprior\nobservational\ncomparative effectiveness studies, individual patient-\nlevel analyses of clinical trials, and indirect treatment\ncomparison network meta-analyses suggesting higher\nef\ufb01cacy and effectiveness of in\ufb02iximab over adalimumab\nand golimumab.4,5,29,30 This may be related to differ-\nences\nin\npharmacokinetics\nand\nbioavailability\nwith\ndifferent dosing schema (weight-based vs \ufb01xed dose)\nand route of administration. The recent Study to Evaluate\nthe Safety and Ef\ufb01cacy of Two Drug Regimens in Subjects"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "patients with moderate\u2013severe ulcerative colitis with\nprior exposure to TNFa antagonists (Figure 2B). With an\nestimated placebo rate of achieving clinical remission of\n3% in included trials, we estimated that 3.2%, 5.6%,\n26.9%, and 26.3% of adalimumab-, vedolizumab-, tofaci-\ntinib-, and ustekinumab-treated patients, respectively,\nwould achieve induction of remission.\nInduction of endoscopic improvement. On direct meta-\nanalysis, tofacitinib and ustekinumab, but not vedolizumab\nor adalimumab, were superior to placebo for induction of\nendoscopic improvement, with minimal heterogeneity\nTable 3. Comparative Ef\ufb01cacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in\nPatients With Moderate\u2013Severe Ulcerative Colitis With Prior Exposure to Tumor Necrosis Factor-a Antagonists Using\nNetwork Meta-Analysis\nInduction of clinical remission\nInduction of endoscopic\nimprovement\nUstekinumab 6 mg/kg\n0.97 (0.11\u20138.72)\n5.99 (1.13\u201331.76)\n10.71 (2.01\u201357.20)"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "and corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis, \nnamely vedolizumab and, more recently, usteki numab. \nHowever, \ntreatment \nwith \nbiologics \nhas \nseveral \nlimit ations, including limited efficacy, primary non-\nresponse, secondary loss of response, immunogenicity,"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 11.0, "text": "should be discussed adequately with patients.\nIntegrating \ufb01ndings from this meta-analysis and other\nstudies, current evidence favors in\ufb02iximab or vedolizu-\nmab\nas\nthe\npreferred\n\ufb01rst-line\nagents\nfor\nmoderate\u2013severe ulcerative colitis. In patients who fail\nin\ufb02iximab, ustekinumab and tofacitinib likely would be\nmost ef\ufb01cacious, and ustekinumab\u2019s superior safety\npro\ufb01le may be attractive in light of recent concerns\naround\nvenous\nthromboembolism\nwith\ntofacitinib.\nHowever, besides quality of evidence, several other fac-\ntors including a balance of risk\u2013bene\ufb01t pro\ufb01le, speci\ufb01c\npatient attributes (age, comorbid conditions including\nrheumatic or dermatologic diseases, and so forth), clin-\nical judgment and experience of the treating physicians,\nvalues\nand\npreferences\nof\npatients\n(dosing\nroute,\nregimen, acceptability of risk\u2013bene\ufb01t trade-offs, and so\nforth), as well as the costs/resources available, are\nimportant to facilitate shared decision making, in devel-"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "vs adalimumab: OR, 11.05; 95% CI, 1.79\u201368.41; moderate CE). Vedolizumab had the lowest risk\nof infections (SUCRA, 0.81), followed by ustekinumab (SUCRA, 0.63) in maintenance trials.\nCONCLUSIONS:\nIn a systematic review and network meta-analysis, we found in\ufb02iximab to be ranked highest in\nbiologic-na\u00efve patients, and ustekinumab and tofacitinib were ranked highest in patients with\nprior exposure to TNF antagonists, for induction of remission and endoscopic improvement in\npatients with moderate to severe ulcerative colitis. More trials of direct comparisons are\nneeded to inform clinical decision making with greater con\ufb01dence.\nKeywords: GRADE; Pharmacotherapy; In\ufb02ammatory Bowel Disease; UC; Comparative Ef\ufb01cacy.\nU\nlcerative colitis affects 1 in 200 to 1 in 400 people\nin Western nations, and its global incidence and\nprevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "immunomodulators (severe disease,  \n \n extraintestinal manifestations)\n\u2022 Ustekinumab (for patients with substantial \n comorbidities or  contraindications to TNF  \n antagonists)\nFirst-line therapy\n\u2022 TNF antagonists: infliximab or adalimumab,  \n preferably in combination with   \n \n \n immunomodulators\n\u2022 Risankizumab or ustekinumab (for patients  \n with substantial comorbidities or  \n \n \n contraindications to TNF antagonists)\nFirst-line therapy\n\u2022 Vedolizumab\n\u2022 Ustekinumab\nFirst-line therapy\n\u2022 Risankizumab or ustekinumab\n\u2022 Vedolizumab\nModerate-to-severely active\nulcerative colitis\nModerate-to-severely active\nulcerative colitis\nModerate-to-severely active\nCrohn's disease\nModerate-to-severely active\nCrohn's disease\nSecond-line therapy\n\u2022 Upadacitinib (or tofacitinib) (for patients with  \n prior failure of infliximab)\n\u2022 Infliximab or ustekinumab (for patients with  \n prior exposure to vedolizumab)\n\u2022 Vedolizumab (moderate disease, for patients  \n who discontinued first-line biologic agent"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 10.0, "text": "subsequent trials of vedolizumab, tofacitinib, and uste-\nkinumab, a signi\ufb01cant proportion of patients may have\nbeen exposed to 2 or more biologic agents before clinical\ntrial intervention, and inherently may be dif\ufb01cult to treat.\nHowever,\ntrials\nof\nustekinumab\nwere\nconducted\nfollowing approval of vedolizumab, and a subset of pa-\ntients in these trials failed multiple TNFa antagonists and\nvedolizumab, conceivably making it a more refractory\npatient population. Despite this, we observed the supe-\nriority of ustekinumab over vedolizumab, suggesting the\neffect likely is real and not confounded by treatment\nrefractoriness.\nIn this study, by updating analyses with the inclusion\nof ustekinumab, accounting for dose change for tofaciti-\nnib, including a head-to-head trial of biologics in\nmoderate\u2013severe\nulcerative\ncolitis,\nappropriately\ncomparing trials of maintenance therapy with different\ndesigns, adding the GRADE framework and assessment\nof absolute effect size, and performing a thorough"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 5.0, "text": "Colitis, 2020. Comorbidity, not patient age, is associated with impaired safety\noutcomes in vedolizumab- and ustekinumab-treated patients with in\ufb02ammatory\nbowel disease-a prospective multicentre cohort study. Aliment. Pharmacol. Ther. 52\n(8), 1366\u20131376.\nAtreya, R., Siegmund, B., 2021. Location is important: differentiation between ileal and\ncolonic crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 18 (8), 544\u2013558.\nBek, S., Nielsen, J.V., Bojesen, A.B., Franke, A., Bank, S., Vogel, U., Andersen, V., 2016.\nSystematic review: genetic biomarkers associated with anti-tnf treatment response in\nin\ufb02ammatory bowel diseases. Aliment. Pharmacol. Ther. 44 (6), 554\u2013567.\nBen-Horin, S., Novack, L., Mao, R., Guo, J., Zhao, Y., Sergienko, R., Zhang, J.,\nKobayashi, T., Hibi, T., Chowers, Y., Peyrin-Biroulet, L., Colombel, J.F., Kaplan, G.G.,\nChen, M.H., 2021. Ef\ufb01cacy of biologic drugs in short-duration versus long-duration\nin\ufb02ammatory bowel disease: a systematic review and an individual-patient data"}]}, {"question": "36 year-old man with moderate to severe extensive ulcerative colitis and spondylarthristis.\n", "answer": "I don't know", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7.0, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2.0, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "meta-analysis. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2022.07.032 \n(2022).\n5. \nBurr, N. E. et al. Efficacy of biological therapies and small molecules in moderate to  \nsevere ulcerative colitis: systematic review and network meta-analysis. Gut 71, 1976\u20131987 \n(2022).\n6. Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid \narthritis. N. Engl. J. Med. 386, 316\u2013326 (2022).\n7. \nBiasci, D. et al. A blood-based prognostic biomarker in IBD. Gut 68, 1386\u20131395 (2019).\n8. Verstockt, B., Parkes, M. & Lee, J. C. How do we predict a patient\u2019s disease course and \nwhether they will respond to specific treatments? Gastroenterology 162, 1383\u20131395 \n(2022).\n9. \nSazonovs, A. et al. HLA-DQA1*05 carriage associated with development of anti-\ndrug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease. \nGastroenterology 158, 189\u2013199 (2020).\n10. Nguyen, N. H., Singh, S. & Sandborn, W. J. Positioning therapies in the management"}, {"title": "", "filename": "otad009.pdf", "page": 0.0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}]}, {"question": "42 year-old woman with moderate ulcerative colitis on azathioprine and not responding to therapy\n", "answer": "I don't know", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "", "filename": "otad009.pdf", "page": 0.0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "in induction trials, we estimated that 58.7%, 40.4%,\n42.7%, 51.9%, 46.5%, and 44.4% of in\ufb02iximab-, adali-\nmumab-, golimumab-, vedolizumab-, tofacitinib-, and\nustekinumab-treated patients, respectively, would ach-\nieve induction of endoscopic improvement.\nSecond-line\npharmacotherapy\nfor\nmoderate\u2013severe\nulcerative colitis. Overall, 7 RCTs including 1580 pa-\ntients with moderate\u2013severe ulcerative colitis with prior\nexposure to TNFa antagonists were identi\ufb01ed. These\nincluded subgroup analyses of trials of adalimumab,21\nvedolizumab,24,25\ntofacitinib,26\nand\nustekinumab.7\nThere were no trials of in\ufb02iximab or golimumab in\npatients with prior exposure to TNFa antagonists who\nmet inclusion criteria. In trials of adalimumab, only pa-\ntients with loss of response or intolerance to a prior\nTNFa antagonist were included. In contrast, in trials of\nvedolizumab, 48% to 58% of patients had inadequate\nresponse to a TNFa antagonist, and in trials of usteki-"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were \nincluded. Phase 2 RCTs were excluded because of their small sample sizes and inclusion of doses not further explored \nin phase 3 RCTs. Summary data from intention-to-treat analyses were extracted from included reports by JSL and PAO. \nThe primary outcome was the induction of clinical remission. A network meta-analysis was done under the frequentist \nframework, obtaining pairwise odds ratios (ORs) and 95% CIs. The surface under the cumulative ranking (SUCRA) \nwas used to rank the included agents for each outcome. Higher SUCRA scores correlate with better efficacy, whereas \nlower SUCRA scores correlate with better safety. Maintenance data on efficacy for treat-straight-through and \nrandomised responder trials are also presented. This study is registered with PROSPERO, CRD42021225329."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 3.0, "text": "Burr et al. \n \n3 of 45 \nABSTRACT \nObjective: Biological therapies and small molecules continue to be evaluated in moderate to \nseverely active ulcerative colitis, but are often studied in placebo-controlled trials, meaning \ntheir relative efficacy and safety is unknown. We examined this in a network meta-analysis.  \nDesign: We searched the literature to October 2021 to identify eligible trials. We judged \nefficacy using clinical remission, endoscopic improvement, or clinical response, and \naccording to previous exposure or non-exposure to anti-tumour necrosis factor (TNF)-\u03b1 \ntherapy. We also assessed safety. We used a random effects model and reported data as \npooled relative risks (RRs) with 95% confidence intervals (CIs). Interventions were ranked \naccording to their P-score. \nResults: We identified 28 trials (12,504 patients). Based on failure to achieve clinical \nremission, upadacitinib 45mg o.d. ranked first versus placebo (RR = 0.73; 95% CI 0.68-0.80,"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "meta-analysis. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2022.07.032 \n(2022).\n5. \nBurr, N. E. et al. Efficacy of biological therapies and small molecules in moderate to  \nsevere ulcerative colitis: systematic review and network meta-analysis. Gut 71, 1976\u20131987 \n(2022).\n6. Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid \narthritis. N. Engl. J. Med. 386, 316\u2013326 (2022).\n7. \nBiasci, D. et al. A blood-based prognostic biomarker in IBD. Gut 68, 1386\u20131395 (2019).\n8. Verstockt, B., Parkes, M. & Lee, J. C. How do we predict a patient\u2019s disease course and \nwhether they will respond to specific treatments? Gastroenterology 162, 1383\u20131395 \n(2022).\n9. \nSazonovs, A. et al. HLA-DQA1*05 carriage associated with development of anti-\ndrug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease. \nGastroenterology 158, 189\u2013199 (2020).\n10. Nguyen, N. H., Singh, S. & Sandborn, W. J. Positioning therapies in the management"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "and corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis, \nnamely vedolizumab and, more recently, usteki numab. \nHowever, \ntreatment \nwith \nbiologics \nhas \nseveral \nlimit ations, including limited efficacy, primary non-\nresponse, secondary loss of response, immunogenicity,"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}]}, {"question": "53 year-old man with moderate to severe extensive ulcerative colitis and low albumin levels\n", "answer": "I don't know", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 11.0, "text": "353:2462\u20132476.\n18.\nJiang XL, Cui HF, Gao J, et al. Low-dose in\ufb02iximab for induction\nand maintenance treatment in Chinese patients with moderate\nto severe active ulcerative colitis. J Clin Gastroenterol 2015;\n49:582\u2013588.\n19.\nXian-Janssen. A study to evaluate the effectiveness and safety\nof in\ufb02iximab in Chinese patients with active ulcerative colitis.\n2015.\nAvailable\nfrom:\nhttps://clinicaltrials.gov/ct2/show/\nNCT01551290. Accessed June 5, 2017.\n20.\nReinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for\ninduction of clinical remission in moderately to severely active\nulcerative colitis: results of a randomised controlled trial. Gut\n2011;60:780\u2013787.\n2190 Singh et al\nClinical Gastroenterology and Hepatology Vol. 18, No. 10"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "meta-analysis. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2022.07.032 \n(2022).\n5. \nBurr, N. E. et al. Efficacy of biological therapies and small molecules in moderate to  \nsevere ulcerative colitis: systematic review and network meta-analysis. Gut 71, 1976\u20131987 \n(2022).\n6. Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid \narthritis. N. Engl. J. Med. 386, 316\u2013326 (2022).\n7. \nBiasci, D. et al. A blood-based prognostic biomarker in IBD. Gut 68, 1386\u20131395 (2019).\n8. Verstockt, B., Parkes, M. & Lee, J. C. How do we predict a patient\u2019s disease course and \nwhether they will respond to specific treatments? Gastroenterology 162, 1383\u20131395 \n(2022).\n9. \nSazonovs, A. et al. HLA-DQA1*05 carriage associated with development of anti-\ndrug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease. \nGastroenterology 158, 189\u2013199 (2020).\n10. Nguyen, N. H., Singh, S. & Sandborn, W. J. Positioning therapies in the management"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "(P A Olivera); Gastroenterology \nand Endoscopy, IRCCS Ospedale \nSan Raffaele and University \nVita-Salute San Raffaele, \nMilano, Italy \n(Prof S Danese MD); INSERM \nNGERE and Department of \nHepatogastroenterology, \nNancy University Hospital, \nLorraine University, \nVandoeuvre-l\u00e9s-Nancy, France \n(Prof L Peyrin-Biroulet MD) \nCorrespondence to: \nProf Laurent Peyrin-Biroulet, \nINSERM NGERE and Department \nof Hepatogastroenterology, \nNancy University Hospital, \nLorraine University, Vandoeuvre-\nl\u00e8s-Nancy F-54511, France \npeyrinbiroulet@gmail.com\nEfficacy and safety of biologics and small molecule drugs for \npatients with moderate-to-severe ulcerative colitis: \na systematic review and network meta-analysis \nJuan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\nSummary\nBackground There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "patients with moderate\u2013severe ulcerative colitis with\nprior exposure to TNFa antagonists (Figure 2B). With an\nestimated placebo rate of achieving clinical remission of\n3% in included trials, we estimated that 3.2%, 5.6%,\n26.9%, and 26.3% of adalimumab-, vedolizumab-, tofaci-\ntinib-, and ustekinumab-treated patients, respectively,\nwould achieve induction of remission.\nInduction of endoscopic improvement. On direct meta-\nanalysis, tofacitinib and ustekinumab, but not vedolizumab\nor adalimumab, were superior to placebo for induction of\nendoscopic improvement, with minimal heterogeneity\nTable 3. Comparative Ef\ufb01cacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in\nPatients With Moderate\u2013Severe Ulcerative Colitis With Prior Exposure to Tumor Necrosis Factor-a Antagonists Using\nNetwork Meta-Analysis\nInduction of clinical remission\nInduction of endoscopic\nimprovement\nUstekinumab 6 mg/kg\n0.97 (0.11\u20138.72)\n5.99 (1.13\u201331.76)\n10.71 (2.01\u201357.20)"}]}, {"question": "42 year-old woman with severe ulcerative colitis and rare fistulating disease\n", "answer": "I don't know", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7.0, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "", "filename": "otad009.pdf", "page": 0.0, "text": "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\nReceived for publication: September 21, 2022. Editorial Decision: January 25, 2023\n \nDownloaded from https://academic.oup.com/crohnscolitis360/article/5/2/otad009/7066911 by National University of Singapore user on 23 May 2023"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 5.0, "text": "Burr et al. \n \n5 of 45 \nSTUDY HIGHLIGHTS \n \nWhat is already known about this subject \n\u2022 Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \nflares of disease activity, some of which may be moderate to severe. \n\u2022 These are usually treated with corticosteroids, which have potentially serious adverse \neffects, so biological therapies and small molecules have been developed and licensed \nfor this indication.  \n\u2022 Although previous network meta-analyses have compared their efficacy and safety, \nthis is a rapidly moving field, and there are already several newer drugs that have \nshown efficacy in phase III clinical trials that were not considered in these. \n \nWhat are the new findings \n\u2022 In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \nfirst in all patients, in patients previously exposed to anti-tumour necrosis factor \n(TNF)-\u03b1 therapies, and in patients na\u00efve to these drugs."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 11.0, "text": "1.\nNgSC,ShiHY,Hamidi N,et al.Worldwideincidence andprevalence\nof in\ufb02ammatory bowel disease in the 21st century: a systematic\nreview of population-based studies. Lancet 2018;390:2769\u20132778.\n2.\nFumery M, Singh S, Dulai PS, et al. Natural history of adult ul-\ncerative colitis in population-based cohorts: a systematic re-\nview. Clin Gastroenterol Hepatol 2018;16:343\u2013356.\n3.\nVester-Andersen MK, Prosberg MV, Jess T, et al. Disease\ncourse and surgery rates in in\ufb02ammatory bowel disease: a\npopulation-based, 7-year follow-up study in the era of immu-\nnomodulating therapy. Am J Gastroenterol 2014;109:705\u2013714.\n4.\nBonovas S, Lytras T, Nikolopoulos G, et al. Systematic review\nwith network meta-analysis: comparative assessment of tofa-\ncitinib and biological therapies for moderate-to-severe ulcera-\ntive colitis. Aliment Pharmacol Ther 2018;47:454\u2013465.\n5.\nSingh S, Fumery M, Sandborn WJ, et al. Systematic review with\nnetwork meta-analysis: \ufb01rst- and second-line pharmacotherapy"}]}, {"question": "68 year-old man with extensive moderate to severe ulcerative colitis who has prostate cancer which has been treated 5 years ago.\n", "answer": "I don't know", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:\nWe searched publication databases through September 30, 2019, for randomized trials of\nadults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\ntofacitinib, or ustekinumab, as \ufb01rst-line or second-line agents, compared with placebo or\nanother active agent. Ef\ufb01cacy outcomes were induction and maintenance of remission and\nendoscopic improvement; safety outcomes were serious adverse events and infections. We\nperformed a \ufb01xed-effects network meta-analysis using the frequentist approach, and calculated\nodds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\nranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\nRecommendations, Assessment, Development and Evaluation).\nRESULTS:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "SYSTEMATIC REVIEWS AND META-ANALYSES\nSiddharth Singh, Section Editor\nFirst- and Second-Line Pharmacotherapies for Patients With\nModerate to Severely Active Ulcerative Colitis: An Updated\nNetwork Meta-Analysis\nSiddharth Singh,*,\u2021 Mohammad Hassan Murad,\u00a7 Mathurin Fumery,j\nParambir S. Dulai,* and William J. Sandborn*\n*Division of Gastroenterology, \u2021Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n\u00a7Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Universit\u00e9 de Picardie Jules Verne, Amiens, France\nBACKGROUND & AIMS:\nWe compared the ef\ufb01cacy and safety of different \ufb01rst-line (biologic-na\u00efve) and second-line\n(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2.0, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "patients with moderate\u2013severe ulcerative colitis with\nprior exposure to TNFa antagonists (Figure 2B). With an\nestimated placebo rate of achieving clinical remission of\n3% in included trials, we estimated that 3.2%, 5.6%,\n26.9%, and 26.3% of adalimumab-, vedolizumab-, tofaci-\ntinib-, and ustekinumab-treated patients, respectively,\nwould achieve induction of remission.\nInduction of endoscopic improvement. On direct meta-\nanalysis, tofacitinib and ustekinumab, but not vedolizumab\nor adalimumab, were superior to placebo for induction of\nendoscopic improvement, with minimal heterogeneity\nTable 3. Comparative Ef\ufb01cacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in\nPatients With Moderate\u2013Severe Ulcerative Colitis With Prior Exposure to Tumor Necrosis Factor-a Antagonists Using\nNetwork Meta-Analysis\nInduction of clinical remission\nInduction of endoscopic\nimprovement\nUstekinumab 6 mg/kg\n0.97 (0.11\u20138.72)\n5.99 (1.13\u201331.76)\n10.71 (2.01\u201357.20)"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "What You Need to Know\nBackground\nA systematic review and network meta-analysis is\nneeded to compare ef\ufb01cacy and safety of \ufb01rst-line\n(biologic-na\u00efve) and second-line (prior exposure to\ntumor necrosis factor [TNF] antagonists) agents for\ntreatment of moderate to severely active ulcerative\ncolitis.\nFindings\nIn\ufb02iximab was ranked highest in biologic-na\u00efve pa-\ntients, and ustekinumab and tofacitinib were ranked\nhighest in patients with prior exposure to TNF an-\ntagonists, for induction of remission and endoscopic\nimprovement. More trials of direct comparisons are\nneeded to inform clinical decision-making with\ngreater con\ufb01dence.\nImplications for patient care\nPatients with moderate to severely active ulcerative\ncolitis should receive in\ufb02iximab or vedolizumab as\n\ufb01rst-line therapy, or ustekinumab or tofacitinib if\nthey have prior exposure to TNF antagonists.\n2180 Singh et al\nClinical Gastroenterology and Hepatology Vol. 18, No. 10"}]}, {"question": "25 year-old man with extensive moderate to severe ulcerative colitis and primary sclerosing cholangitis with decompensated cirrhosis.\n", "answer": "I don't know", "sources": [{"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 5.0, "text": "Group, G.C.S., 2018. Ef\ufb01cacy of adalimumab in patients with crohn's disease and\nsymptomatic small bowel stricture: a multicentre, prospective, observational cohort\n(creole) study. Gut 67 (1), 53\u201360.\nChandrakumar, A., Georgy, M., Agarwal, P., Jong, G.W. t, El-Matary, W., 2019. Anti-\nsaccharomyces cerevisiae antibodies as a prognostic biomarker in children with\ncrohn disease. J. Pediatr. Gastroenterol. Nutr. 69 (1), 82\u201387.\nCheng, D., Cushing, K.C., Cai, T., Ananthakrishnan, A.N., 2021. Safety and ef\ufb01cacy of\ntumor necrosis factor antagonists in older patients with ulcerative colitis: patient-\nlevel pooled analysis of data from randomized trials. Clin. Gastroenterol. Hepatol. 19\n(5), 939\u2013946.\nChristensen, B., Micic, D., Gibson, P.R., Yarur, A., Bellaguarda, E., Corsello, P.,\nGaetano, J.N., Kinnucan, J., Rao, V.L., Reddy, S., Singh, S., Pekow, J., Rubin, D.T.,\n2018. Vedolizumab in patients with concurrent primary sclerosing cholangitis and"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 5.0, "text": "Gaetano, J.N., Kinnucan, J., Rao, V.L., Reddy, S., Singh, S., Pekow, J., Rubin, D.T.,\n2018. Vedolizumab in patients with concurrent primary sclerosing cholangitis and\nin\ufb02ammatory bowel disease does not improve liver biochemistry but is safe and\neffective for the bowel disease. Aliment. Pharmacol. Ther. 47 (6), 753\u2013762.\nCleynen, I., Boucher, G., Jostins, L., Schumm, L.P., Zeissig, S., Ahmad, T., Andersen, V.,\nAndrews, J.M., Annese, V., Brand, S., Brant, S.R., Cho, J.H., Daly, M.J., Dubinsky, M.,\nDuerr, R.H., Ferguson, L.R., Franke, A., Gearry, R.B., Goyette, P., Hakonarson, H.,\nHalfvarson, J., Hov, J.R., Huang, H., Kennedy, N.A., Kupcinskas, L., Lawrance, I.C.,\nLee, J.C., Satsangi, J., Schreiber, S., Theatre, E., van der Meulen-de Jong, A.E.,\nWeersma, R.K., Wilson, D.C., International In\ufb02ammatory Bowel Disease Genetics, C.,\nParkes, M., Vermeire, S., Rioux, J.D., Mans\ufb01eld, J., Silverberg, M.S., Radford-"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7.0, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 7.0, "text": "multiple sclerosis and ulcerative colitis in the USA. Another \nmeta-analysis showed that sphingosine 1-phosphate \nmodulators are associated with an increased risk of herpes \nzoster infection and transient cardiovascular events.45\nOur study has several limitations besides the usual \nlimitations of network meta-analyses. First, data from \nsome clinical trials with newer small molecule drugs were \nextracted from conference abstracts, and the full data could \nnot be completely analysed. Notably, we could only analyse \noutcomes for the overall population as the main analysis, \nand not according to previous exposure to biologics. We \ndid do an exploratory analysis according to previous \nbiologic exposure, but data for upadacitinib could not be \nincluded. Second, no phase 3 RCTs with etrasimod or \nTD-1473 were found; results from phase 3 clinical trials \ntesting novel small molecule drugs (eg, etrasimod) in \npatients with moderate-to-severe ulcerative colitis are"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "", "filename": "otad009.pdf", "page": 0.0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}]}, {"question": "48 year-old woman with distal moderate to severe ulcerative colitis who prioritizes a rapid response to treatment.\n", "answer": "I don't know", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "and corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis, \nnamely vedolizumab and, more recently, usteki numab. \nHowever, \ntreatment \nwith \nbiologics \nhas \nseveral \nlimit ations, including limited efficacy, primary non-\nresponse, secondary loss of response, immunogenicity,"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2.0, "text": "con\ufb01dence. The rating of indirect estimates starts at the\nlowest rating of the 2 pairwise estimates that contribute\nas \ufb01rst-order loops to the indirect estimate but can be\nrated down further for imprecision or intransitivity\n(dissimilarity between studies in terms of clinical or\nFigure 1. (A) Network of included studies with the available\ndirect comparisons for induction of clinical remission in bio-\nlogic-na\u00efve patients with moderate\u2013severe ulcerative colitis.\nThe size of the nodes and the thickness of the edges are\nweighted according to the number of studies evaluating each\ntreatment and direct comparison, respectively. (B) Network of\nincluded studies with the available direct comparisons for\ninduction of clinical remission in patients with prior tumor\nnecrosis\nfactor\n(TNF)a\nantagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct"}, {"title": "", "filename": "otad009.pdf", "page": 0.0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "in induction trials, we estimated that 58.7%, 40.4%,\n42.7%, 51.9%, 46.5%, and 44.4% of in\ufb02iximab-, adali-\nmumab-, golimumab-, vedolizumab-, tofacitinib-, and\nustekinumab-treated patients, respectively, would ach-\nieve induction of endoscopic improvement.\nSecond-line\npharmacotherapy\nfor\nmoderate\u2013severe\nulcerative colitis. Overall, 7 RCTs including 1580 pa-\ntients with moderate\u2013severe ulcerative colitis with prior\nexposure to TNFa antagonists were identi\ufb01ed. These\nincluded subgroup analyses of trials of adalimumab,21\nvedolizumab,24,25\ntofacitinib,26\nand\nustekinumab.7\nThere were no trials of in\ufb02iximab or golimumab in\npatients with prior exposure to TNFa antagonists who\nmet inclusion criteria. In trials of adalimumab, only pa-\ntients with loss of response or intolerance to a prior\nTNFa antagonist were included. In contrast, in trials of\nvedolizumab, 48% to 58% of patients had inadequate\nresponse to a TNFa antagonist, and in trials of usteki-"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "patients with moderate\u2013severe ulcerative colitis with\nprior exposure to TNFa antagonists (Figure 2B). With an\nestimated placebo rate of achieving clinical remission of\n3% in included trials, we estimated that 3.2%, 5.6%,\n26.9%, and 26.3% of adalimumab-, vedolizumab-, tofaci-\ntinib-, and ustekinumab-treated patients, respectively,\nwould achieve induction of remission.\nInduction of endoscopic improvement. On direct meta-\nanalysis, tofacitinib and ustekinumab, but not vedolizumab\nor adalimumab, were superior to placebo for induction of\nendoscopic improvement, with minimal heterogeneity\nTable 3. Comparative Ef\ufb01cacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in\nPatients With Moderate\u2013Severe Ulcerative Colitis With Prior Exposure to Tumor Necrosis Factor-a Antagonists Using\nNetwork Meta-Analysis\nInduction of clinical remission\nInduction of endoscopic\nimprovement\nUstekinumab 6 mg/kg\n0.97 (0.11\u20138.72)\n5.99 (1.13\u201331.76)\n10.71 (2.01\u201357.20)"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}]}, {"question": "36 year-old woman with moderate to severe ulcerative colitis who has lost response to tofacitinib.\n", "answer": "Based on the given patient profile, the patient has moderate to severe ulcerative colitis and has lost response to tofacitinib. Considering the patient's age and prior response to tofacitinib, the top two choices of biological drugs could be Infliximab and Ustekinumab.\n\n1. Infliximab:\n   - Advantages: Infliximab is a preferred first-line agent for moderate to severe ulcerative colitis. It has a strong effect size for inducing clinical remission.\n   - Disadvantages: As with any medication, there is a risk of side effects, including serious infections. Some patients may also develop anti-drug antibodies to Infliximab, reducing its effectiveness over time.\n\n2. Ustekinumab:\n   - Advantages: Ustekinumab has been found to be efficacious in patients who fail infliximab. It also has a superior safety profile, which may be attractive for patients concerned about side effects.\n   - Disadvantages: The overall event rate for important safety outcomes is low, but as with any medication, there is a risk of side effects.\n\nPlease note that the choice of treatment should be made in consultation with the patient, taking into account the patient's preferences, the balance of risk-benefit profile, and the costs/resources available.\n\nOutput:\n[\n  {\n    \"drug_name\": \"Infliximab\",\n    \"advantages\": \"Preferred first-line agent for moderate to severe ulcerative colitis with a strong effect size for inducing clinical remission.\",\n    \"disadvantages\": \"Risk of side effects including serious infections. Potential for development of anti-drug antibodies reducing effectiveness over time.\"\n  },\n  {\n    \"drug_name\": \"Ustekinumab\",\n    \"advantages\": \"Efficacious in patients who fail infliximab with a superior safety profile.\",\n    \"disadvantages\": \"Risk of side effects. The overall event rate for important safety outcomes is low.\"\n  }\n]", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 11.0, "text": "should be discussed adequately with patients.\nIntegrating \ufb01ndings from this meta-analysis and other\nstudies, current evidence favors in\ufb02iximab or vedolizu-\nmab\nas\nthe\npreferred\n\ufb01rst-line\nagents\nfor\nmoderate\u2013severe ulcerative colitis. In patients who fail\nin\ufb02iximab, ustekinumab and tofacitinib likely would be\nmost ef\ufb01cacious, and ustekinumab\u2019s superior safety\npro\ufb01le may be attractive in light of recent concerns\naround\nvenous\nthromboembolism\nwith\ntofacitinib.\nHowever, besides quality of evidence, several other fac-\ntors including a balance of risk\u2013bene\ufb01t pro\ufb01le, speci\ufb01c\npatient attributes (age, comorbid conditions including\nrheumatic or dermatologic diseases, and so forth), clin-\nical judgment and experience of the treating physicians,\nvalues\nand\npreferences\nof\npatients\n(dosing\nroute,\nregimen, acceptability of risk\u2013bene\ufb01t trade-offs, and so\nforth), as well as the costs/resources available, are\nimportant to facilitate shared decision making, in devel-"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "patients with moderate\u2013severe ulcerative colitis with\nprior exposure to TNFa antagonists (Figure 2B). With an\nestimated placebo rate of achieving clinical remission of\n3% in included trials, we estimated that 3.2%, 5.6%,\n26.9%, and 26.3% of adalimumab-, vedolizumab-, tofaci-\ntinib-, and ustekinumab-treated patients, respectively,\nwould achieve induction of remission.\nInduction of endoscopic improvement. On direct meta-\nanalysis, tofacitinib and ustekinumab, but not vedolizumab\nor adalimumab, were superior to placebo for induction of\nendoscopic improvement, with minimal heterogeneity\nTable 3. Comparative Ef\ufb01cacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in\nPatients With Moderate\u2013Severe Ulcerative Colitis With Prior Exposure to Tumor Necrosis Factor-a Antagonists Using\nNetwork Meta-Analysis\nInduction of clinical remission\nInduction of endoscopic\nimprovement\nUstekinumab 6 mg/kg\n0.97 (0.11\u20138.72)\n5.99 (1.13\u201331.76)\n10.71 (2.01\u201357.20)"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "in induction trials, we estimated that 58.7%, 40.4%,\n42.7%, 51.9%, 46.5%, and 44.4% of in\ufb02iximab-, adali-\nmumab-, golimumab-, vedolizumab-, tofacitinib-, and\nustekinumab-treated patients, respectively, would ach-\nieve induction of endoscopic improvement.\nSecond-line\npharmacotherapy\nfor\nmoderate\u2013severe\nulcerative colitis. Overall, 7 RCTs including 1580 pa-\ntients with moderate\u2013severe ulcerative colitis with prior\nexposure to TNFa antagonists were identi\ufb01ed. These\nincluded subgroup analyses of trials of adalimumab,21\nvedolizumab,24,25\ntofacitinib,26\nand\nustekinumab.7\nThere were no trials of in\ufb02iximab or golimumab in\npatients with prior exposure to TNFa antagonists who\nmet inclusion criteria. In trials of adalimumab, only pa-\ntients with loss of response or intolerance to a prior\nTNFa antagonist were included. In contrast, in trials of\nvedolizumab, 48% to 58% of patients had inadequate\nresponse to a TNFa antagonist, and in trials of usteki-"}, {"title": "", "filename": "otad009.pdf", "page": 0.0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "meta-analysis. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2022.07.032 \n(2022).\n5. \nBurr, N. E. et al. Efficacy of biological therapies and small molecules in moderate to  \nsevere ulcerative colitis: systematic review and network meta-analysis. Gut 71, 1976\u20131987 \n(2022).\n6. Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid \narthritis. N. Engl. J. Med. 386, 316\u2013326 (2022).\n7. \nBiasci, D. et al. A blood-based prognostic biomarker in IBD. Gut 68, 1386\u20131395 (2019).\n8. Verstockt, B., Parkes, M. & Lee, J. C. How do we predict a patient\u2019s disease course and \nwhether they will respond to specific treatments? Gastroenterology 162, 1383\u20131395 \n(2022).\n9. \nSazonovs, A. et al. HLA-DQA1*05 carriage associated with development of anti-\ndrug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease. \nGastroenterology 158, 189\u2013199 (2020).\n10. Nguyen, N. H., Singh, S. & Sandborn, W. J. Positioning therapies in the management"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 6.0, "text": "investigators for all trials, except trials of tofacitinib and\nustekinumab, which were read by blinded central\nreaders.7,26 Overall, the studies were deemed to be at\nlow risk of bias, and all included studies were industry-\nsponsored.\nInduction Therapy\nFirst-line\npharmacotherapy\nfor\nmoderate\u2013severe\nulcerative colitis. Overall, 15 RCTs including 3747 bio-\nlogic-na\u00efve patients with moderate\u2013severe ulcerative\ncolitis, treated with in\ufb02iximab (4 trials, 667 patients),\nadalimumab (4 trials, 1046 patients), golimumab (2 tri-\nals, 586 patients), vedolizumab (3 trials, 630 patients),\ntofacitinib (2 trials, 520 patients), and ustekinumab (1\ntrial, 298 patients) were included; 1 trial compared\nadalimumab vs vedolizumab.\nInduction\nof\nclinical\nremission. On\ndirect\nmeta-\nanalysis, all agents were superior to placebo for induc-\ntion of clinical remission, and effect size was strongest\nfor in\ufb02iximab (OR, 4.07; 95% CI, 2.68\u20136.16) and vedoli-\nzumab (OR, 3.10; 95% CI, 1.53\u20136.26), with minimal to"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 8.0, "text": "tagonists. Overall, tofacitinib (SUCRA, 0.91) and ustekinu-\nmab (SUCRA, 0.83) were ranked highest for inducing\nendoscopic\nimprovement\nin\npatients\nwith\nmoderate\u2013severe ulcerative colitis with prior exposure to\nTNFa antagonists (Figure 2B). With an estimated placebo\nrate of achieving endoscopic improvement of 15% in\nincluded trials, we estimated that 16.3%, 17.7%, 45.4%,\nand 39.1% of adalimumab-, vedolizumab-, tofacitinib-, and\nustekinumab-treated patients, respectively, would achieve\nendoscopic improvement.\nComparative\nsafety\nof\ninduction\ntherapy. Supple-\nmentary Table 1 summarizes rate of all adverse events,\nadverse events resulting in treatment discontinuation,\nserious adverse events, and serious infections in trials of\ninduction therapy. Data on safety strati\ufb01ed by TNFa\nantagonist exposure status was not reported, and the\noverall event rate for important safety outcomes was\nlow; hence, a formal network meta-analysis was not\nperformed. Overall, the median rate of serious adverse"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:\nWe searched publication databases through September 30, 2019, for randomized trials of\nadults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\ntofacitinib, or ustekinumab, as \ufb01rst-line or second-line agents, compared with placebo or\nanother active agent. Ef\ufb01cacy outcomes were induction and maintenance of remission and\nendoscopic improvement; safety outcomes were serious adverse events and infections. We\nperformed a \ufb01xed-effects network meta-analysis using the frequentist approach, and calculated\nodds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\nranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\nRecommendations, Assessment, Development and Evaluation).\nRESULTS:"}]}, {"question": "18 year-old man with moderate to severe extensive ulcerative colitis and pyoderma gangrenosum.\n", "answer": "[\n{\n\"drug_name\": \"Infliximab\",\n\"advantages\": \"Infliximab is a biologic therapy that has revolutionized therapeutics for ulcerative colitis, enabling better disease control in terms of increasing the rates of mucosal healing, deep remission, and corticosteroid-free remission, and improving quality of life. It is also effective in treating extraintestinal manifestations such as pyoderma gangrenosum.\",\n\"disadvantages\": \"Infliximab has several limitations, including limited efficacy in some patients, primary non-response, secondary loss of response, and immunogenicity. It also carries a risk of infection and malignancy.\"\n},\n{\n\"drug_name\": \"Vedolizumab\",\n\"advantages\": \"Vedolizumab is another biologic therapy that has been approved for the treatment of moderate-to-severe ulcerative colitis. It is effective in inducing and maintaining remission in patients with ulcerative colitis.\",\n\"disadvantages\": \"Vedolizumab may not be as effective as Infliximab in treating extraintestinal manifestations such as pyoderma gangrenosum. It also carries a risk of infection and malignancy.\"\n}\n]", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "patients with moderate\u2013severe ulcerative colitis with\nprior exposure to TNFa antagonists (Figure 2B). With an\nestimated placebo rate of achieving clinical remission of\n3% in included trials, we estimated that 3.2%, 5.6%,\n26.9%, and 26.3% of adalimumab-, vedolizumab-, tofaci-\ntinib-, and ustekinumab-treated patients, respectively,\nwould achieve induction of remission.\nInduction of endoscopic improvement. On direct meta-\nanalysis, tofacitinib and ustekinumab, but not vedolizumab\nor adalimumab, were superior to placebo for induction of\nendoscopic improvement, with minimal heterogeneity\nTable 3. Comparative Ef\ufb01cacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in\nPatients With Moderate\u2013Severe Ulcerative Colitis With Prior Exposure to Tumor Necrosis Factor-a Antagonists Using\nNetwork Meta-Analysis\nInduction of clinical remission\nInduction of endoscopic\nimprovement\nUstekinumab 6 mg/kg\n0.97 (0.11\u20138.72)\n5.99 (1.13\u201331.76)\n10.71 (2.01\u201357.20)"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 5.0, "text": "Chen, M.H., 2021. Ef\ufb01cacy of biologic drugs in short-duration versus long-duration\nin\ufb02ammatory bowel disease: a systematic review and an individual-patient data\nmeta-analysis of randomized controlled trials. Gastroenterology 162 (2), 482\u2013494.\nBen Abdallah, H., Fogh, K., Vestergaard, C., Bech, R., 2021. Pyoderma gangrenosum and\ninterleukin inhibitors: a semi-systematic review. Dermatology 1\u20138.\nBilliet, T., Papamichael, K., de Bruyn, M., Verstockt, B., Cleynen, I., Princen, F., Singh, S.,\nFerrante, M., Van Assche, G., Vermeire, S., 2015. A matrix-based model predicts\nprimary response to in\ufb02iximab in crohn's disease. J Crohns Colitis 9 (12), 1120\u20131126.\nBonovas, S., Fiorino, G., Allocca, M., Lytras, T., Nikolopoulos, G.K., Peyrin-Biroulet, L.,\nDanese, S., 2016. Biologic therapies and risk of infection and malignancy in patients\nwith in\ufb02ammatory bowel disease: a systematic review and network meta-analysis.\nClin. Gastroenterol. Hepatol. 14 (10), 1385\u20131397."}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "and corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis, \nnamely vedolizumab and, more recently, usteki numab. \nHowever, \ntreatment \nwith \nbiologics \nhas \nseveral \nlimit ations, including limited efficacy, primary non-\nresponse, secondary loss of response, immunogenicity,"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7.0, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}]}, {"question": "58 year-old woman with moderate to severe distal ulcerative colitis and optic neuritis.\n", "answer": "I don't know", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "SYSTEMATIC REVIEWS AND META-ANALYSES\nSiddharth Singh, Section Editor\nFirst- and Second-Line Pharmacotherapies for Patients With\nModerate to Severely Active Ulcerative Colitis: An Updated\nNetwork Meta-Analysis\nSiddharth Singh,*,\u2021 Mohammad Hassan Murad,\u00a7 Mathurin Fumery,j\nParambir S. Dulai,* and William J. Sandborn*\n*Division of Gastroenterology, \u2021Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n\u00a7Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Universit\u00e9 de Picardie Jules Verne, Amiens, France\nBACKGROUND & AIMS:\nWe compared the ef\ufb01cacy and safety of different \ufb01rst-line (biologic-na\u00efve) and second-line\n(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2.0, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7.0, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 7.0, "text": "TD-1473 were found; results from phase 3 clinical trials \ntesting novel small molecule drugs (eg, etrasimod) in \npatients with moderate-to-severe ulcerative colitis are \nexpected soon, which will warrant further updates \nof this analysis. Additionally, several newer biologics, \nespecially anti-IL-23 drugs (ie, risankizumab, mirikizumab, \nguselkumab, and brazikumab), are also expected to yield \npositive results in phase 3 clinical trials, so these data \nshould also be considered in the future to determine \ntheir position in treatment algorithms. Third, thorough"}]}, {"question": "55 year-old man with moderate to severe extensive ulcerative colitis and colonic polyps with high grade dysplasia found 2 years ago.\n", "answer": "I don't know", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7.0, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:\nWe searched publication databases through September 30, 2019, for randomized trials of\nadults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\ntofacitinib, or ustekinumab, as \ufb01rst-line or second-line agents, compared with placebo or\nanother active agent. Ef\ufb01cacy outcomes were induction and maintenance of remission and\nendoscopic improvement; safety outcomes were serious adverse events and infections. We\nperformed a \ufb01xed-effects network meta-analysis using the frequentist approach, and calculated\nodds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\nranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\nRecommendations, Assessment, Development and Evaluation).\nRESULTS:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 10.0, "text": "ulcerative\ncolitis,\nappropriately\ncomparing trials of maintenance therapy with different\ndesigns, adding the GRADE framework and assessment\nof absolute effect size, and performing a thorough\nquantitative and qualitative assessment of the safety of\ndifferent therapies, we have been able to contextualize\nour con\ufb01dence in the summary estimates for different\ncomparisons, and more thoroughly inform positioning of\ndifferent\nagents\nused\nin\nthe\ntreatment\nof\nmoderate\u2013severe ulcerative colitis. We acknowledge that\nthere is a paucity of head-to-head trials to truly inform\ncomparative ef\ufb01cacy and safety. However, it is important\nto note that across trials of induction therapy, key\ninclusion/exclusion criteria, outcome de\ufb01nitions, and\npatient and clinical characteristics, co-interventions were\ncomparable across trials, which facilitated this network\nmeta-analysis.\nBesides inherent limitations of individual trials, there\nwere limitations to our analyses. A thorough comparative"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 11.0, "text": "tive colitis. Aliment Pharmacol Ther 2018;47:454\u2013465.\n5.\nSingh S, Fumery M, Sandborn WJ, et al. Systematic review with\nnetwork meta-analysis: \ufb01rst- and second-line pharmacotherapy\nfor moderate-severe ulcerative colitis. Aliment Pharmacol Ther\n2018;47:162\u2013175.\n6.\nSands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. Vedolizumab\nversus adalimumab for moderate-to-severe ulcerative colitis.\nN Engl J Med 2019;381:1215\u20131226.\n7.\nSands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as\ninduction and maintenance therapy for ulcerative colitis. N Engl\nJ Med 2019;381:1201\u20131214.\n8.\nPuhan MA, Schunemann HJ, Murad MH, et al. A GRADE Working\nGroup approach for rating the quality of treatment effect esti-\nmates from network meta-analysis. BMJ 2014;349:g5630.\n9.\nHutton B, Salanti G, Caldwell DM, et al. The PRISMA extension\nstatement for reporting of systematic reviews incorporating\nnetwork meta-analyses of health care interventions: checklist\nand explanations. Ann Intern Med 2015;162:777\u2013784.\n10."}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 5.0, "text": "Burr et al. \n \n5 of 45 \nSTUDY HIGHLIGHTS \n \nWhat is already known about this subject \n\u2022 Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \nflares of disease activity, some of which may be moderate to severe. \n\u2022 These are usually treated with corticosteroids, which have potentially serious adverse \neffects, so biological therapies and small molecules have been developed and licensed \nfor this indication.  \n\u2022 Although previous network meta-analyses have compared their efficacy and safety, \nthis is a rapidly moving field, and there are already several newer drugs that have \nshown efficacy in phase III clinical trials that were not considered in these. \n \nWhat are the new findings \n\u2022 In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \nfirst in all patients, in patients previously exposed to anti-tumour necrosis factor \n(TNF)-\u03b1 therapies, and in patients na\u00efve to these drugs."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2.0, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}]}, {"question": "27 year-old woman with moderate to severe extensive ulcerative colitis who prefers medication with oral formulation.\n", "answer": "Based on the patient's profile, the top two choices of biological drugs would be Vedolizumab (VDZ) and Ustekinumab (UST). \n\n1. Vedolizumab (VDZ)\n   - Advantages: VDZ has been shown to be superior in achieving clinical remission and endoscopic improvement in moderate to severe UC. It has a good safety profile and is generally well-tolerated.\n   - Disadvantages: VDZ is administered via intravenous infusion, which may not align with the patient's preference for an oral formulation. It may also not be feasible due to payer preference.\n\n2. Ustekinumab (UST)\n   - Advantages: UST is an effective option for moderate UC with a good safety profile. It may be a better first-choice option than TNFi due to its safety profile.\n   - Disadvantages: Similar to VDZ, UST is also administered via intravenous infusion, which may not be preferred by the patient. It may also not be feasible due to payer preference.\n\nPlease note that the final decision should be made after a thorough discussion with the patient, considering her preferences, the severity of her condition, and other factors such as cost and availability of the drugs.\n\n[{\"drug_name\": \"Vedolizumab (VDZ)\", \"advantages\": \"Superior in achieving clinical remission and endoscopic improvement in moderate to severe UC. Good safety profile.\", \"disadvantages\": \"Administered via intravenous infusion, may not align with patient's preference for oral formulation. May not be feasible due to payer preference.\"}, {\"drug_name\": \"Ustekinumab (UST)\", \"advantages\": \"Effective option for moderate UC with good safety profile. May be a better first-choice option than TNFi due to safety profile.\", \"disadvantages\": \"Administered via intravenous infusion, may not be preferred by the patient. May not be feasible due to payer preference.\"}]", "sources": [{"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 8.0, "text": "micronutrients in diet, as well as food additives, processing,\nand packaging.104 Currently, there is no recommendation\nfor whole foods\u2013based management of IBD, but future\nstudies will delineate this further.\nEarly Therapy of Ulcerative Colitis\nIn UC, mild disease can be managed with oral and/or\ntopical mesalamine therapy, generally with adequate con-\ntrol of disease.38 For moderate UC, VDZ and UST are effec-\ntive options,105,106 and may be better \ufb01rst-choice options\nthan TNFi, given safety pro\ufb01le. In the VARSITY trial, the only\nhead-to-head trial of 2 biologics (n \u00bc 769), VDZ was supe-\nrior to ADA in achieving clinical remission (31.3% vs 22.5%;\nP \u00bc .006) and endoscopic improvement (39.7% vs 27.7%; P\n< .001) in moderate to severe UC.105 In case VDZ or UST\nmay not be feasible due to payer preference, TNFi, partic-\nularly IFX, is an effective option with good safety pro\ufb01le.107\nThiopurines may be considered in moderate UC after\nweighing risks against bene\ufb01ts.64 In patients with severe UC"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 11.0, "text": "should be discussed adequately with patients.\nIntegrating \ufb01ndings from this meta-analysis and other\nstudies, current evidence favors in\ufb02iximab or vedolizu-\nmab\nas\nthe\npreferred\n\ufb01rst-line\nagents\nfor\nmoderate\u2013severe ulcerative colitis. In patients who fail\nin\ufb02iximab, ustekinumab and tofacitinib likely would be\nmost ef\ufb01cacious, and ustekinumab\u2019s superior safety\npro\ufb01le may be attractive in light of recent concerns\naround\nvenous\nthromboembolism\nwith\ntofacitinib.\nHowever, besides quality of evidence, several other fac-\ntors including a balance of risk\u2013bene\ufb01t pro\ufb01le, speci\ufb01c\npatient attributes (age, comorbid conditions including\nrheumatic or dermatologic diseases, and so forth), clin-\nical judgment and experience of the treating physicians,\nvalues\nand\npreferences\nof\npatients\n(dosing\nroute,\nregimen, acceptability of risk\u2013bene\ufb01t trade-offs, and so\nforth), as well as the costs/resources available, are\nimportant to facilitate shared decision making, in devel-"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "and corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis, \nnamely vedolizumab and, more recently, usteki numab. \nHowever, \ntreatment \nwith \nbiologics \nhas \nseveral \nlimit ations, including limited efficacy, primary non-\nresponse, secondary loss of response, immunogenicity,"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 7.0, "text": "TD-1473 were found; results from phase 3 clinical trials \ntesting novel small molecule drugs (eg, etrasimod) in \npatients with moderate-to-severe ulcerative colitis are \nexpected soon, which will warrant further updates \nof this analysis. Additionally, several newer biologics, \nespecially anti-IL-23 drugs (ie, risankizumab, mirikizumab, \nguselkumab, and brazikumab), are also expected to yield \npositive results in phase 3 clinical trials, so these data \nshould also be considered in the future to determine \ntheir position in treatment algorithms. Third, thorough"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8.0, "text": "moderately to severely active ulcerative colitis: a systematic review \nand network meta-analysis. Ann Intern Med 2014; 160: 704\u201311.\n11 \nSingh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \nwith network meta-analysis: first- and second-line pharmacotherapy \nfor moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n47: 162\u201375.\n12 \nBonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \nSystematic review with network meta-analysis: comparative \nassessment of tofacitinib and biological therapies for moderate-to-\nsevere ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454\u201365.\n13 \nSingh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \nsecond-line pharmacotherapies for patients with moderate to \nseverely active ulcerative colitis: an updated network meta-analysis. \nClin Gastroenterol Hepatol 2020; 18: 2179\u201391.e6.\n14 \nMoher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \nitems for systematic reviews and meta-analyses: the PRISMA"}, {"title": "", "filename": "otad009.pdf", "page": 0.0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}]}, {"question": "41 year-old man with moderate to severe distal ulcerative colitis and alocpecia areata.\n", "answer": "I don't know", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7.0, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2.0, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "meta-analysis. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2022.07.032 \n(2022).\n5. \nBurr, N. E. et al. Efficacy of biological therapies and small molecules in moderate to  \nsevere ulcerative colitis: systematic review and network meta-analysis. Gut 71, 1976\u20131987 \n(2022).\n6. Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid \narthritis. N. Engl. J. Med. 386, 316\u2013326 (2022).\n7. \nBiasci, D. et al. A blood-based prognostic biomarker in IBD. Gut 68, 1386\u20131395 (2019).\n8. Verstockt, B., Parkes, M. & Lee, J. C. How do we predict a patient\u2019s disease course and \nwhether they will respond to specific treatments? Gastroenterology 162, 1383\u20131395 \n(2022).\n9. \nSazonovs, A. et al. HLA-DQA1*05 carriage associated with development of anti-\ndrug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease. \nGastroenterology 158, 189\u2013199 (2020).\n10. Nguyen, N. H., Singh, S. & Sandborn, W. J. Positioning therapies in the management"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 1.0, "text": "Burr et al. \n \n1 of 45 \nAccepted 2nd December 2021 \nTITLE PAGE \n \nTitle: Efficacy of Biological Therapies and Small Molecules in Moderate to Severe \nUlcerative Colitis: Systematic Review and Network Meta-analysis. \n \nShort title: Network Meta-analysis of Biological Therapies and Small Molecules for UC. \n \nAuthors: Nicholas E. Burr MD1,2, David J Gracie PhD1,2, Christopher J. Black PhD1,2*, \nAlexander C. Ford MD1,2*. \n*Joint last author \n \n1Leeds Gastroenterology Institute, St. James\u2019s University Hospital, Leeds, UK. \n2Leeds Institute of Medical Research at St. James\u2019s, University of Leeds, Leeds, UK. \n \nAbbreviations: \nCI \n \nconfidence interval \nRCT \n \nrandomised controlled trial \nRR \n \nrelative risk \nTNF \n \ntumour necrosis factor \nUC \n \nulcerative colitis \n \nCorrespondence: \nProfessor Alex Ford \nLeeds Gastroenterology Institute \nRoom 125 \n4th Floor"}]}, {"question": "38 year-old woman with moderate to severe ulcerative colitis and pulmonary tuberculosis which was treated 2 years ago.", "answer": "I don't know", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1.0, "text": "network\nmeta-analysis\nfor\nhealth\ncare\ndecision\nmaking.10\nStudy Selection\nWe conducted 2 separate pairwise and network\nmeta-analyses of induction therapy to estimate the\ncomparative ef\ufb01cacy of different agents in biologic-\nna\u00efve patients and in patients with prior exposure to\nTNFa antagonists for management of moderate\u2013severe\nulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2.0, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1.0, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7.0, "text": "patients with moderate\u2013severe ulcerative colitis with\nprior exposure to TNFa antagonists (Figure 2B). With an\nestimated placebo rate of achieving clinical remission of\n3% in included trials, we estimated that 3.2%, 5.6%,\n26.9%, and 26.3% of adalimumab-, vedolizumab-, tofaci-\ntinib-, and ustekinumab-treated patients, respectively,\nwould achieve induction of remission.\nInduction of endoscopic improvement. On direct meta-\nanalysis, tofacitinib and ustekinumab, but not vedolizumab\nor adalimumab, were superior to placebo for induction of\nendoscopic improvement, with minimal heterogeneity\nTable 3. Comparative Ef\ufb01cacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in\nPatients With Moderate\u2013Severe Ulcerative Colitis With Prior Exposure to Tumor Necrosis Factor-a Antagonists Using\nNetwork Meta-Analysis\nInduction of clinical remission\nInduction of endoscopic\nimprovement\nUstekinumab 6 mg/kg\n0.97 (0.11\u20138.72)\n5.99 (1.13\u201331.76)\n10.71 (2.01\u201357.20)"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:\nWe searched publication databases through September 30, 2019, for randomized trials of\nadults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\ntofacitinib, or ustekinumab, as \ufb01rst-line or second-line agents, compared with placebo or\nanother active agent. Ef\ufb01cacy outcomes were induction and maintenance of remission and\nendoscopic improvement; safety outcomes were serious adverse events and infections. We\nperformed a \ufb01xed-effects network meta-analysis using the frequentist approach, and calculated\nodds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\nranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\nRecommendations, Assessment, Development and Evaluation).\nRESULTS:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0.0, "text": "SYSTEMATIC REVIEWS AND META-ANALYSES\nSiddharth Singh, Section Editor\nFirst- and Second-Line Pharmacotherapies for Patients With\nModerate to Severely Active Ulcerative Colitis: An Updated\nNetwork Meta-Analysis\nSiddharth Singh,*,\u2021 Mohammad Hassan Murad,\u00a7 Mathurin Fumery,j\nParambir S. Dulai,* and William J. Sandborn*\n*Division of Gastroenterology, \u2021Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n\u00a7Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Universit\u00e9 de Picardie Jules Verne, Amiens, France\nBACKGROUND & AIMS:\nWe compared the ef\ufb01cacy and safety of different \ufb01rst-line (biologic-na\u00efve) and second-line\n(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0.0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3.0, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2.0, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}]}]}